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Nearly three quarters of all strokes occur in people over 65, and within this older 
group, strokes are more common and more severe in women than men. Added to this 
disease burden, is the lack of suitable therapies for stroke patients. My research focused 
on identifying a stroke therapy that is effective for older female stroke patients. Middle-
aged female rats were used as a model system to understand disparities in stroke 
outcomes in middle-aged postmenopausal women. Our laboratory has shown previously 
that post-stroke Insulin like growth factor (IGF)-I treatment reduces blood brain barrier 
permeability and decreases infarct volumes in middle aged female rats. In three major 
experiments, this dissertation tested the hypothesis that IGF-1 acts on the endothelium to 
reduce neuroinflammation and improve recovery. Through Experiment 1, we found that 
IGF-1 treatment provided by intracerebroventricular injection, decreased extravasation 
of CD4+ cells into the ischemic hemisphere. Similarly, IGF-1 reduced protein transfer 
across a monolayer of brain microvessel endothelial cells derived from middle aged 
females, further implicating this cell type as the locus of IGF-1 action. Experiment 2 
showed that IGF-1 stabilized the actin cytoskeleleton and adhesion of endothelial cells 
exposed to OGD and preserved microvessel diameter and length in vivo after stroke. 
Both in vivo and in vitro, IGF-1’s effects were reversed with concurrent exposure to the 
IGFR antagonist JB-1. Additionally, while IGF-1 treatment improved microvessel 
morphology in early acute phase of stroke, sensory-motor behavior was improved during 
both the early and late acute phase of stroke. Experiment 3 tested the novel hypothesis 
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that IGF-1 secreted by astrocytes is neuroprotective. With age, astrocyte derived IGF-1 
decreases, and by using IGF-1 gene transfer targeted to astrocytes, we found reduced 
stroke-induced sensory motor impairment and decreased blood brain barrier 
permeability, without affecting infarct volumes. Collectively, these data support and 
suggest that the aging endothelium and astrocyte interaction may be critical for post 















I would like to dedicate this work to four women who have given me much more than 
one word can contain, but I will audaciously try: 
 
 To my mother, LaRonda Rue Alford—for life. 
 To my grandmother, Leola Alford—for love. 
 To my aunt, Theresa Alford-Moore—for hope. 









I would like to thank my committee chair, Dr. Sohrabji, and my committee 
members, Dr. Welsh, Dr. White, and Dr. Li for their guidance and support throughout 
the course of this research. 
Thanks also go to my friends and colleagues and the department faculty and staff 
for making my time at Texas A&M University a great experience.  
Finally, thanks to my mother and my aunt for their encouragement and to my 




CONTRIBUTORS AND FUNDING SOURCES 
 
Contributors 
This work was supervised by a dissertation committee consisting of Professor 
Farida Sohrabji of the Department of Neuroscience and Experimental Therapeutics, 
Professor Jane Welsh of the Department of Veterinary Integrative Biosciences, Assistant 
Professor Jianrong Li of the Department of Veterinary Integrative Biosciences, and 
Associate Professor Brad White of the Department of Neuroscience and Experimental 
Therapeutics.  
Assistance with data analysis for all studies was provided by Professor Farida 
Sohrabji. In the first study which was published in 2016, Chanell Dawson and Tiffany 
Heard provided technical assistance, and Professor Robert Alaniz assisted with 
experimental design. In the second study which was published in 2019, laboratory 
technicians Ms. Tiffany Heard, Mr. Victor Cardenas and Ms. Jessica Lee provided 
technical assistance and surgical and cell culture expertise was provided by Professor 
Shameena Bake. Professor Homa Khosravian assisted with experimental design in the 
second study as well. In the third study, which was published in 2017, surgical assistance 
was provided by Professor Shameena Bake. In addition, Graduate student Nihal Salem 
provided expert assistance with qRT-PCR. Graduate students Miriam Aceves and Mabel 
Terminal provided assistance with flow studies, and Post-doctoral fellow Min-Jung Park 
provided assistance with statistical analysis of cytokines.  
 vii 
 
All other work conducted for this dissertation was completed by the student 
independently.  
Funding Sources 
Graduate study was supported by a fellowship from Texas A&M University 








DEDICATION .................................................................................................................. iv 
ACKNOWLEDGEMENTS ............................................................................................... v 
CONTRIBUTORS AND FUNDING SOURCES ............................................................. vi 
TABLE OF CONTENTS ............................................................................................... viii 
LIST OF FIGURES ........................................................................................................... xi 
LIST OF TABLES ......................................................................................................... xiii 
1. INTRODUCTION: STROKE ........................................................................................ 1 
1.1. The Burden of Stroke in the United States .............................................................. 2 
1.2. Unmodifiable Disparities in Stroke: Age; Sex; Race & Income ............................. 3 
1.3. The Need for More Acute Interventions in Acute Stroke ....................................... 5 
1.4. Animal Models for Stroke ....................................................................................... 6 
1.5. Insulin-like Growth Factor & Stroke ...................................................................... 8 
1.6. References ............................................................................................................. 12 
2. FIRST STUDY: INSULIN-LIKE GROWTH FACTOR (IGF)-1 MODULATES 
ENDOTHELIAL BLOOD BRAIN BARRIER FUNCTION IN ISCHEMIC 
MIDDLE-AGED FEMALE RATS .................................................................................. 28 
2.1. Overview of The First Study ................................................................................. 28 
2.2. Introduction ........................................................................................................... 29 
2.3. Materials and Methods .......................................................................................... 31 
2.3.1. Analysis of immune cell transfer to the brain post stroke .............................. 32 
2.3.2. Middle cerebral artery occlusion (MCAo) ..................................................... 32 
2.3.3. Isolation of central nervous system infiltrates and staining ........................... 33 
2.3.4. Characterization of endothelial cell cultures .................................................. 37 
2.3.5. Oxygen-glucose deprivation (OGD) procedure ............................................. 37 
2.3.6. Lactate dehydrogenase (LDH) assay .............................................................. 38 
2.3.7. In vitro permeability assay: FITC-BSA transfer assay .................................. 38 
2.3.8. Statistical analysis .......................................................................................... 38 
2.4. Results ................................................................................................................... 39 
 ix 
 
2.4.1. Effect of IGF-I on immune cell extravasation into the ischemic brain .......... 39 
2.4.2. Characterization of primary BMECs cultures ................................................ 41 
2.4.3. OGD and reoxygenation cause cellular damage in middle-aged BMECs ..... 43 
2.4.4. Effect of IGF-I on permeability of BMEC monolayers exposed to OGD 
reoxygenation ........................................................................................................... 45 
2.5. Discussion ............................................................................................................. 47 
2.6. Abbreviations ........................................................................................................ 50 
2.7. References ............................................................................................................. 51 
3. SECOND STUDY: INSULIN-LIKE GROWTH FACTOR (IGF)-1 TREATMENT 
STABILIZES THE MICROVASCULAR CYTOSKELETON UNDER ISCHEMIC 
CONDITIONS ................................................................................................................. 60 
3.1. Overview of the Second Study .............................................................................. 60 
3.2. Introduction ........................................................................................................... 61 
3.3. Materials and Methods .......................................................................................... 63 
3.3.1. In vitro studies ................................................................................................ 63 
3.3.2. In vivo studies ................................................................................................ 66 
3.3.3. Statistical analysis .......................................................................................... 71 
3.4. Results ................................................................................................................... 71 
3.4.1. IGF-1 does not reduce OGD-induced cell death ............................................ 71 
3.4.2. IGF-1 preserved the actin cytoskeleton of human brain microvascular 
endothelial cells after OGD ...................................................................................... 73 
3.4.3. Impact of IGF-1 on microvessel architecture in vivo ..................................... 75 
3.4.4. Effect of post-stroke IGF-1 treatment on vinculin staining ........................... 78 
3.4.5. Effect of post-stroke IGF-1 treatment on microvessel morphology ............... 81 
3.5. Discussion ............................................................................................................. 84 
3.6. References ............................................................................................................. 90 
4. THIRD STUDY: ASTROCYTE-SPECIFIC INSULIN-LIKE GROWTH 
FACTOR-1 (IGF-1) GENE TRANSFER IN AGING FEMALE RATS IMPROVES 
STROKE OUTCOMES ................................................................................................. 101 
4.1. Overview of the Third Study ............................................................................... 101 
4.2. Introduction ......................................................................................................... 102 
4.3. Materials and Methods ........................................................................................ 105 
4.3.1. Animals ........................................................................................................ 105 
4.3.2. Adenovirus constructs .................................................................................. 105 
4.3.3. Surgical Procedures ...................................................................................... 106 
4.3.4. Confirmation of AAV5 localization ............................................................. 108 
4.3.5. Infarct Analysis ............................................................................................ 109 
4.3.6. Behavioral analysis ....................................................................................... 109 
4.3.7. Cross-midline placing test ............................................................................ 110 
4.3.8. Neurological Score ....................................................................................... 111 
 x 
 
4.3.9. Physiological measurements ........................................................................ 112 
4.3.10. Quantitative RT-PCR ................................................................................. 113 
4.3.11. Cell preparation .......................................................................................... 115 
4.3.12. For astrocyte separation .............................................................................. 116 
4.3.13. For flow cytometry of immune cells .......................................................... 116 
4.3.14. ELISA Assays ............................................................................................ 117 
4.3.15. Statistical analyses ...................................................................................... 120 
4.4. Results ................................................................................................................. 120 
4.4.1. Characterization of AAV5 Integration ......................................................... 120 
4.4.2. Post-Ischemic Survival ................................................................................. 123 
4.4.3. Physiological measures affected by MCAo at the early acute period (2 
days) post-stroke ..................................................................................................... 124 
4.4.4. Post-stroke sensory-motor behavioral outcomes .......................................... 127 
4.4.5. Blood brain barrier permeability .................................................................. 129 
4.4.6. Stroke-induced Inflammation ....................................................................... 131 
4.4.7. Impact of rAAV5-GFAP-hIGF-1 in a permanent ischemia model .............. 135 
4.5. Discussion ........................................................................................................... 137 
4.6. Main Points ......................................................................................................... 142 
4.7. References ........................................................................................................... 142 
5. CONCLUSIONS ........................................................................................................ 156 
5.1. Insulin-like Growth Factor-1 Protects the Blood Brain Barrier .......................... 156 
5.2. Further Work and Challenges ............................................................................. 159 
5.2.1. The Therapeutic Window of IGF-1 .............................................................. 159 
5.2.2. The Long Term Effects & Toxicity of IGF-1 ............................................... 160 
5.2.3. Molecular Pathways of IGF-1 ...................................................................... 161 
5.2.4. Interaction of Endothelial Cells and Astrocytes ........................................... 162 
5.2.5. Stem Cell Therapy ........................................................................................ 163 
5.3. Final Words ......................................................................................................... 164 




LIST OF FIGURES 
Page 
Figure 2-1: IGF-I regulates immune cell infiltration into ischemic cortex ...................... 40 
Figure 2-2: Characterization of BMECs from adult rat brain cortex ............................... 42 
Figure 2-3: Effect of OGD, OGD and reoxygenation, and IGF-I on BMECs from 
middle-aged females ......................................................................................... 44 
Figure 2-4: OGD and reoxygenation induced changes in barrier properties of 
endothelial cells ................................................................................................ 46 
Figure 3-1: Graphical Representation of the Effect of IGF-1 on hBMECs cell 
adhesion and cytoskeletal organization. ........................................................... 72 
Figure 3-2: Cytology of the Effect of IGF-1 on hBMECs cell adhesion and 
cytoskeletal organization. ................................................................................. 74 
Figure 3-3: Lectin staining of human brain microvessel endothelial cells (hBMEC) 
under normoxic and OGD conditions ............................................................... 76 
Figure 3-4: Effect of post-stroke IGF-1 treatment on neurological function 1 day after 
MCAo ............................................................................................................... 78 
Figure 3-5: Effect of post-stroke IGF-1 treatment on vinculin expression (A) 1d post 
stroke ................................................................................................................. 79 
Figure 3-6: Effect of post-stroke IGF-1 treatment on microvessel morphology. ............. 83 
Figure 4-1: AAV5 constructs. ........................................................................................ 106 
Figure 4-2: Integration of the AAV5 in the brain. ......................................................... 122 
Figure 4-3: Post-ischemic survival ................................................................................. 124 
Figure 4-4: Low dose post-ischemic outcomes .............................................................. 126 
Figure 4-5: Vibrissae-Evoked Forelimb Placing Test .................................................... 128 
Figure 4-6: Serum Analysis ............................................................................................ 130 
Figure 4-7: Infiltrating regulatory T-cell Analysis ......................................................... 132 
Figure 4-8: Infiltrating M1/M2 Macrophage Analysis .................................................. 134 
 xii 
 
Figure 4-9: Permanent MCAo Model ............................................................................ 136 
 
xiii 
LIST OF TABLES 
Page 
Table 2-1: Table of antibodies used in the first study ...................................................... 34 
Table 4-1: Gene Sequence .............................................................................................. 114 
1. INTRODUCTION: STROKE
Stroke is a classically defined as a neurological deficient and/or dysfunction of 
vascular origin attributed to the acute focal injury of central nervous system (CNS) 
(Goldstein, Bertels, & Davis, 1989). In 2013, the American Heart Association expanded 
the definition to include acute injuries to the CNS caused by vascular deficiencies and/or 
dysfunctions that do not present clinically (Sacco et al., 2013). Center of Disease Control 
categorizes strokes into three types, ischemic, hemorrhage, and transient ischemic attack, 
with ischemic and hemorrhage being the most commonly documented (Go et al., 2014). 
For strokes that do present clinically, the common symptoms are dysphasia (difficulty 
swallowing), dysarthria (motor speech disorders), hemianopia (defective vision), 
weakness, ataxia (lack of muscle control), sensory loss, neglect, and, at worst, death (van 
der Worp & van Gijn, 2007). Ischemic stroke presents most commonly and occurs when 
the blood study to CNS is interrupted, temporarily or permanently, depriving cells of 
nutrients and oxygen (Hinkle & Guanci, 2007). This interruption leads to a cascade of 
cellular responses, including excretion of toxic excitatory amino acids, free-radical 
formation, and harmful inflammation (van der Worp & van Gijn, 2007). These events 
are thought to lead to CNS injury and death. 
Ischemic stroke is a multifactorial disease, having both genetic and environment 
etiologies. Anatomically, the most appreciated causes of ischemic stroke are due to 
thrombi (obstruction of a blood vessel by a blood clots forming locally) and emboli 
(obstruction due to an embolus, unattached mass, from elsewhere in the body) occluding 
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small and large arteries (Hinkle & Guanci, 2007). The middle cerebral artery (MCA), the 
largest branch of the internal carotid artery, is the largest cerebral artery and the most 
commonly affected artery in stroke syndromes (Adams et al., 1996; Grotta, 1988). After 
onset, a central core, an area of low perfusion and high nutrition deprivation, develops 
and is surrounded by another area of higher perfusion and less metabolic disturbance 
known as the ischemia penumbra (Hinkle & Guanci, 2007). The size of infarction, tissue 
death, depends on the level of perfusion within the central core and penumbra and any 
perfusion changes that occur during recovery as the penumbra incorporates into the 
central core. The size and location of infarction has direct consequence on clinical 
outcomes and recovery. Overall, thirty-day case fatality rates for ischemic stroke 
generally range between 10 and 17% (Hinkle & Guanci, 2007). The survival and 
prognosis for stroke varies significantly with unmodifiable factors, such as income, race, 
age, and sex (Go et al., 2014). 
1.1. The Burden of Stroke in the United States 
Stroke is a fourth leading of death in the United States (U.S.). Though the stroke 
mortality rate decreased by 35% between 2001 and 2011 (Mozaffarian et. al., 2015; 
Rasmussen, 2015), stroke stills exacts a catastrophic toll on U.S. families and is a 
substantial U.S. financial health burden. Stroke causes approximately 1 out of every 20 
deaths in the U.S. (Mozaffarian et. al., 2015) On average, every 4 minutes, 6 people in 
the U.S. will have a stroke, and of those 6 individuals, at least 1 of them will die 
(Mozaffarian et. al., 2015). It is projected that 1 in every 4 people in the U.S. will have a 
stroke in their lifetime (Sachdeva, Saeed, Jani, & Razak, 2016). For stroke survivors, 
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there is an almost certain chance of disability (Ovbiagele et al., 2013), and care is 
expensive. Immediate direct costs for non–nursing home stroke care constitute >10.7% 
of the Medicare budget and >1.7% of overall national health expenditures. However, the 
long-term care, which many patient require, including nursing home care costs more, 
and indirect costs of stroke care as premature death and lost productivity are greater than 
all direct costs combined (Ovbiagele et al., 2013). The emotional and psychological 
distress on families, care givers, health practitioners, and patients is uncalculatable but 
immense, and all these costs are projected to increase as the U.S. population ages 
(Sachdeva et al., 2016). 
1.2. Unmodifiable Disparities in Stroke: Age; Sex; Race & Income 
Young people rarely gets strokes (Onorato et al., 2003). Although the incidence 
of young stroke is increasing (Swerdel et al., 2016), adults between the ages of 15-44 
only account for less than 10 percent of stroke (George, Tong, Kuklina, & Labarthe, 
2011). Young adults (> 40 years old) tend to have better stroke outcomes (Nedeltchev et 
al., 2005). However, the effects of a young stroke can be long-lasting and debilitating, 
disrupting an individual’s life course in its prime and leading to years of unemployment 
(M. Lawrence & Kinn, 2012; Maaijwee et al., 2014). As ages increases over 50, stroke 
outcomes get increase dire, increasing morbidity and mortality, and decreasing long-
term quality-of-life. The influence of age is so striking it is used in several predictive 
models of stroke (Bejot et al., 2012; Counsell, Dennis, McDowall, & Warlow, 2002; 
Koennecke et al., 2011; Weimar et al., 2004). 
 4 
 
Males and females respond differently to stroke depending largely but not solely on age 
(Lutfiyya, Ng, Asner, & Lipsky, 2009; Turtzo & McCullough, 2008). Women tend to 
have strokes at older ages compared to men when stroke outcomes are worse (Ahnstedt, 
McCullough, & Cipolla, 2016). After menopause (~51), women exhibit a sharp increases 
in stroke risk (Towfighi, Saver, Engelhardt, & Ovbiagele, 2007). Understanding the sex 
differences in stroke is confounded by age, since women have strokes later in life, 
however even after controlling for other unmodifiable factor, such as age, comorbidities, 
and stroke severity, women still have worse post-stroke clinical outcomes (Turtzo & 
McCullough, 2008).    
More women die each year of stroke than men (Girijala, Sohrabji, & Bush, 
2016). Overall, stroke is the fourth leading cause of death in U.S, but, for women, it is 
third; for men, the fifth (Sohrabji, Park, & Mahnke, 2017). Over their lifetime, women 
have an increased risk for stroke compared to men and women live longer (Dotson & 
Offner, 2017). Hence, there are more women stroke survivors than men (3.8 of the 6.8 
million) (Spychala, Honarpisheh, & McCullough, 2017), and these women stroke 
survivors are more likely to need extensive care. Women are twice as likely as men to be 
discharged to long-term care upon hospital discharge, placing a disproportionate burden 
on the health care system (Turtzo & McCullough, 2008). Women are also more likely 
than men to report and experience depression after stroke, further complicating recovery 
(Turtzo & McCullough, 2008). 
Investigating sex differences in stroke must involve biological, social, and 
political strategies since they are significant variations in stroke mortality and post-
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stroke outcomes in women based solely on socioeconomic status and race (Albright et 
al., 2016). Black women for example have the worse post-stroke outcomes than any 
other groups of women (Albright et al., 2016). 
There are major race disparities in stroke for Black Americans. Stroke mortality 
is two times higher for the black population (Centers for Disease & Prevention, 2005; 
Gaines & Burke, 1995; Horn, Deutscher, Smout, DeJong, & Putman, 2010). This 
population faces increased stroke morbidity and increased post-stroke complications 
compared to whites (Kittner et al., 1993). Despite having a higher prevalence within the 
community, Blacks, as a whole, have less understanding of stroke and its complications 
(Sharrief, Johnson, Abada, & Urrutia, 2016). The cause of these disparities are 
multifaceted, however socioeconomics plays a significant role in perpetuating this 
inequality. Blacks tend to have lower educational attainment, lower incomes, less 
degrees of social support, less health care access, and less trust of health care 
practitioners (Gaines & Burke, 1995; Howard et al., 2016; Kind et al., 2010). All these 
factors combine to create a perfect storm for stroke health inequality. 
1.3. The Need for More Acute Interventions in Acute Stroke 
Tissue plasminogen (tPA) is the gold standard care for acute ischemic stroke 
(Almasi, Razmeh, Habibi, & Rezaee, 2016; Anaissie et al., 2016). For two decades, 
since June 1996, U.S. physicians have used tPA as the sole recommended therapy for 
early-presenting acute stroke patient (Ciccone et al., 2013; Elgendy, Mahmoud, 
Mansoor, Mojadidi, & Bavry, 2016). tPA works by dissolving the clot and improving 
reperfusion. If given within its optimal time window, tPA significantly reduces mortality 
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and morbidity. Unfortunately, 4.5 hours after stroke onset, tPA’s detriments outweigh its 
benefits and use is not recommended (Elgendy et al., 2016).  
Beside short therapeutic window (>4.5 hours), tPA has other disadvantages, 
including increased risk of hemorrhage and a low rate of recanalization, re-opening of 
the occluded vessel (Elgendy et al., 2016). Initially, only 3-4% of stroke patients receive 
tPA due mostly to the short therapeutic window (de Los Rios la Rosa et al., 2012). 
Though, from 2003 -2011, its use has double (Lewandowski et al., 2015). But despite 
increased use, many eligible patients are not treated. But even they are lucky enough to 
receive tPA, half of these treated patients do not completely recover or die (Ciccone et 
al., 2013).   
Acute stroke is also treated with endovascular procedures, however these 
procedures are more invasive and have strict criteria. Overall, most patients receive only 
palliative care and rehabilitation after a stroke (Ciccone et al., 2013). Because of the 
limited options for acute interventions, there are a strong drive to uncover for more 
effective stroke therapies, especially in populations affected disproportionately, such as 
women. 
1.4. Animal Models for Stroke 
To discover new therapies, researchers have relied heavily on animal models to 
mimic stroke pathology in the laboratory (Kumar, Aakriti, & Gupta, 2016). The use of 
these designed animals models is necessary to predict the efficacy, relevance, and 
toxicity of new therapeutics before human trials (Bacigaluppi, Comi, & Hermann, 2010; 
Durukan & Tatlisumak, 2009). Most researchers used rats and mice, however rabbits, 
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gerbils, cats, dogs, pigs and monkeys are used to provide a more thorough understanding 
of the stroke pathology and therapeutic efficiency (Kumar et al., 2016). No model is 
prefect, and each animal model offers its own advantages and disadvantages. Rats have a 
particular advantage in stroke research, due to their close resemblance with humans in 
vascular anatomy and physiology and availability of scientific reagents (Kumar et al., 
2016). Changes in socialized, psychological, and tactile behaviors, which are extremely 
important in humans, are difficult to model in the rats (Yin, Guven, & Dietis, 2016). But, 
importantly, some unmodifiable factors, particularly sex and age, reflect the human 
condition (Liu & McCullough, 2011).  
Female rats have been useful in studying women’s age-related increase in stroke 
mortality (Koebele & Bimonte-Nelson, 2016). Like in humans, at mid-age, female rats 
undergo a hormonal and reproductive shift midlife that results in a loss of fertility 
(Gorodeski, 2000). Middle-aged (10-12 month old) female rats also have worse post-
stroke outcomes in measured behavior and larger infarcts compared to the young adult 
(6-7 month old) female rats, mirroring the age-dependent worsening of clinical outcomes 
seen in women (Selvamani & Sohrabji, 2010b). 
Initially, laboratory of this dissertation replaced estrogen in the acyclic middle-
aged female rats. However, estrogen replacement was seen to be neurotoxic (Selvamani 
& Sohrabji, 2010a). In searching for hormones to provide as treatment, our laboratory 
uncovered neuroprotection effects of insulin-like growth factor (IGF)-1 as powerful 




1.5. Insulin-like Growth Factor & Stroke 
Insulin-like growth factor-1 discovered in 1957, as an important hormone in 
child development, however the precise action of IGF-I wasn’t appreciated until the 
1980s will genetic recombination became a prominent force in the scientific world, 
leading to the creation of recombinant human IGF-I (Laron, 2001; Piotrowska et al., 
2013). 
IGF-1 is a single-chain 70 amino acids polypeptide which has three 
intramolecular disulfide bridge and is approximately 7.5 kilo Daltons (Daughaday, 
1997). Most of the available IGF-1 is produced in the liver(Laron, 2004). Systemically, 
IGF-1 is carried, like many hormones, on binding proteins (IGF-BP), specifically 
IGFBP-3 carries most of the IGF-1 in the blood at a 1:1 ratio (Ranke, 2015). IGF-1 has 
always been associated with growth. For example, in humans, IGF-1 levels reaches its 
peak during puberty, a period of high physical growth (Soliman, De Sanctis, Elalaily, & 
Bedair, 2014). The main symptom of IGF-1 deficiency, clinically known as Laron 
deficiency, is short statue (Laron, Lilos, & Klinger, 1993). The main treatment for Laron 
deficiency is IGF-1 replacement, thus highlighting the important of IGF-1 in growth 
(Puche & Castilla-Cortazar, 2012). 
IGF-1 and its receptor, IGF-1R, are implicated in the regulation of protein 
turnover and exert potent mitogenic, differentiating effects in cells (Laviola, Natalicchio, 
& Giorgino, 2007). IGF-1 binds at high affinity to IGF-1R, which is a cell surface 
receptor and at low affinity of insulin reception, which has a high homology to IGF-1R 
(M. C. Lawrence, McKern, & Ward, 2007). However, most of the IGF-1’s observed 
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effects, such as cell growth, differentiation, and survival, are mediated through the IGF-1 
receptor signaling (Delafontaine, Song, & Li, 2004). 
IGF-1R activates small G-protein Ras, which in turn activates Raf and 
extracellular-signal-regulated kinase (ERK) kinase (Mendoza, Er, & Blenis, 2011). This 
pathway is coupled to transcription and mitogenic factors (Kiessling & Rogler, 2015). 
Additionally, IGF-1R has been linked the MAP kinase cascade, Jnk-1 and -2 cascade, 
and p38 MAP kinase, which also has a role in survival (Latres et al., 2005). Insulin-like 
growth factor 1 and the insulin pathways closely related in terms of biological activity 
and primary sequence (M. C. Lawrence et al., 2007; Xu & Messina, 2009).   
When Peter Gluckman published his findings in the early 1990s that exogenous 
IGF-1 is neuroprotective in hypoxia-ischemic conditions, it was also known the insulin 
offered some neuroprotection at high levels (Gluckman et al., 1992). IGF-1, however, 
exerts its functions of cell growth and development, cell survival, learning and memory 
on the IGF-1 receptor (IGF-1R) (Guan, Bennet, Gluckman, & Gunn, 2003; Zhang, Jiang, 
& Meng, 2015). The neuroprotection offered by insulin is now believed to be due to 
insulin’s promiscuity on IGF-1R (Duarte, Santos, Oliveira, & Rego, 2005; Duarte, 
Santos, Oliveira, Santos, & Rego, 2008). IGFs were first known as “sulfation factors” 
because they were first defined by their involvement in cartilage sulfation; this name 
then changed to the somatomedins due to their ability to mediate growth hormone 
actions (Haddad, 1967). 
In the brain, IGF-1 activates canonical PI3K-Akt and Ras-Raf-MAP pathways in 
several cell types and is produced in all major CNS cell types in the cortex, 
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hippocampus, cerebellum, and hypothalamus(Dyer, Vahdatpour, Sanfeliu, & Tropea, 
2016). IGF-1 has consequential importance in neurogenesis, neuroplasticity, 
neurodevelopment, and neuro-degenerative disease (Guan & Gluckman, 2009). IGF-1 
reduces cell loss and improves long-term neurological function and IGF-1 signaling 
dysfunction has been linked to several models of neurodegeneration, such as a diabetic 
peripheral neuropathy (DPN) (Rauskolb, Dombert, & Sendtner, 2017), Alzheimer's (AD) 
(Vidal et al., 2016), Parkinson's (PD) (Bernhard et al., 2016), and Huntington's diseases 
(HD) (Humbert et al., 2002).  
IGF-1 availability decreases with age (D. K. Lewis, Bake, Thomas, Jezierski, & 
Sohrabji, 2010; Selvamani & Sohrabji, 2010a). Though the cause of the decline of IGF-1 
secretion over an organism’s lifespan is unknown (Arvat, Broglio, & Ghigo, 2000; 
Muller et al., 2012). Decreases in growth hormone pulses over an organism’s lifespan 
may cause the decrease in IGF-1 secretion (A. L. Lewis et al., 2015; Owens, Johnson, 
Campbell, & Ballard, 1990). The age-related reduction in spontaneous and GHRH-
induced GH secretion pulses reflect age-related changes in neurotransmitter control 
(Ghigo et al., 2000). Low IGF-1 levels have neuropathological consequences and have 
been correlated with frailty and decreases in cognitive abilities (Vidal et al., 2016). 
Unfortunately, IGF-1 levels decrease with age, the incidence of stroke increases 
(Bake et al., 2014; Selvamani & Sohrabji, 2010a). Some studies report low IGF-1 
availability as an independent risk factor for stroke. IGF-1’s neuroprotective properties 
have been witnessed in a number of male animal models, showcasing that administration 
of IGF-1 post-stroke in male rats up to 6 hours after ischemia yielded a time dependent 
 11 
 
reduction of infarct volume. The sooner after the MCAo that IGF-1 is given the greater 
the effect. However, gene transfer in gerbils also demonstrated increased survival and 
recovery when the transfer occurred 30 min after ischemia using the Sendai virus. 
Using the aging female model, the laboratory had shown that IGF-1 decreases the 
amount of Evans blue dye extravasation into the brain, as well as cause a global decrease 
of both pro- and anti-inflammatory cytokines and chemokines (Bake et al., 2014). After 
microRNA profiling, putative gene targets associated with extracellular matrix, survival 
pathways, and blood-brain barrier/endothelial function has been implicated in IGF-1 
treatment post-stroke (Bake et al., 2014). Taken together, the downstream effects of 
IGF-1 signaling strongly suggests a strengthening of the blood brain barrier as its 
mechanism of action.  
The research presented here will analyze the neuroprotective effect of IGF-1 on 
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2. FIRST STUDY: INSULIN-LIKE GROWTH FACTOR (IGF)-1 MODULATES 
ENDOTHELIAL BLOOD BRAIN BARRIER FUNCTION IN ISCHEMIC MIDDLE-
AGED FEMALE RATS1 
 
2.1. Overview of The First Study 
In comparison with young females, middle-aged female rats sustain greater 
cerebral infarction and worse functional recovery after stroke. These poorer stroke 
outcomes in middle-aged females are associated with an age-related reduction in IGF-I 
levels. Poststroke IGF-I treatment decreases infarct volume in older females and lowers 
the expression of cytokines in the ischemic hemisphere. IGF-I also reduces transfer of 
Evans blue dye to the brain, suggesting that this peptide may also promote blood-brain 
barrier function. To test the hypothesis that IGF-I may act at the blood-brain barrier in 
ischemic stroke, 2 approaches were used. In the first approach, middle-aged female rats 
were subjected to middle cerebral artery occlusion and treated with IGF-I after 
reperfusion. Mononuclear cells from the ischemic hemisphere were stained for CD4 or 
triple-labeled for CD4/CD25/FoxP3 and subjected to flow analyses. Both cohorts of 
cells were significantly reduced in IGF-I–treated animals compared with those in vehicle 
controls. Reduced trafficking of immune cells to the ischemic site suggests that blood-
brain barrier integrity is better maintained in IGF-I–treated animals. The second 
                                                 
1 Reprinted with permission from Bake S, Okoreeh AK, Alaniz RC, Sohrabji F. Insulin-
Like Growth Factor (IGF)-I Modulates Endothelial Blood-Brain Barrier Function in 




approach directly tested the effect of IGF-I on barrier function of aging endothelial cells. 
Accordingly, brain microvascular endothelial cells from middle-aged female rats were 
cultured ex vivo and subjected to ischemic conditions (oxygen-glucose deprivation). 
IGF-I treatment significantly reduced the transfer of fluorescently labeled BSA across 
the endothelial monolayer as well as cellular internalization of fluorescein 
isothiocyanate–BSA compared with those in vehicle-treated cultures, Collectively, these 
data support the hypothesis that IGF-I improves blood-brain barrier function in middle-
aged females. 
2.2. Introduction 
Middle-aged females experience more severe stroke and poor functional recovery 
(Andersen et al., 2010; Towfighi et al., 2007), and this may be associated with the 
reduction in ovarian hormones and a concomitant decrease in other endocrine factors 
such as IGF-I (Selvamani et al., 2010). In rodent studies, greater infarct volume in 
acyclic middle-aged female rats (Selvamani and Sohrahji, 2010) is correlated with low 
levels of circulating and brain IGF-I expression compared with that in young females 
(Selvamani et al., 2010; Muller et al.; 2012). 
The neuroprotective actions of IGF-I have been shown in several injury models, 
although the precise mechanisms underlying its actions are not well understood. IGF-I 
receptors are found on numerous brain cell types including neurons (Andersson, et al. 
1988; Shemer, et al. 1987), astrocytes (Liu et al., 1994), endothelial cells (Torres-
Aleman, et al., 1990; Chisalita, et al., 2004; Ungvari, et al., 2012), and microglia 
(Chesik, et al, 13). Furthermore, the IGF-I receptor, which is a ligand-activated receptor 
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tyrosine kinase, recruits the phosphatidylinositol 3-kinase/AKT/mammalian target of 
rapamycin survival pathway, and mediates inhibitory phosphorylation of the glycogen 
synthase kinase 3β, which promotes neuronal apoptosis (Hetman et al., 2000; Rangone et 
al., 2004). Hence IGF-I may promote survival of diverse cell types in the ischemic brain, 
including neurons and endothelial cells. 
The effective maintenance of blood-brain barrier properties requires the 
coordinate action of endothelial cells, astrocytes, and pericytes (Abbott, et al., 1992; 
Ballabh, et al., 2004). Several lines of evidence from our previous work indicate that 
IGF-I may act on the blood-brain barrier to promote neuroprotection in ischemic stroke. 
Ischemic tissue from IGF-I and control animals subject to microRNA profiling and 
KEGG (Kyoto Encyclopedia of Genes and Genomes) analysis identified putative gene 
targets associated with extracellular matrix, survival pathways, and blood-brain 
barrier/endothelial function in middle-aged ischemic brain (Bake, et al., 2014). In 
addition, an IGF-I–mediated reduction in infarct volume was preceded by improved 
blood-brain barrier function as assessed by transfer of Evans dye. Finally, IGF-I also 
reduced the levels of proinflammatory and anti-inflammatory cytokines in the ischemic 
brain (Bake, et al., 2014). Postischemic inflammation plays a crucial role in stroke 
pathology (Nilupul Perera, et al., 2006; Amantea, et al., 2009), and signals from the 
ischemic brain can mobilize lymphocytes and macrophages, which are readily trafficked 
into the ischemic site (del Zoppo, et al., 2001; Wang, et. al., 2007; Gelderblom, et al. 
2009; Jin, et al., 2010). IGF-I–mediated reductions in cytokines indirectly support the 
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hypothesis that this peptide may preserve barrier function by preventing extravasation of 
immune cells. 
Therefore, in the present study we used 2 approaches to test the hypothesis that 
IGF-I promotes barrier function. In the first approach, an in vivo ischemic stroke model 
was used to determine whether IGF-I would affect the extent of peripheral immune cells 
recruited to the ischemic brain. In the second approach, an ex vivo system was used to 
determine the effect of IGF-I on primary brain endothelial cells from middle-aged 
female rats. Both approaches support the hypothesis that the neuroprotective effects of 
IGF may be mediated via direct action on endothelial cells to preserve blood-brain 
barrier function and reduce the trafficking of peripheral immune cells after stroke. 
2.3. Materials and Methods 
A total of 60 female Sprague-Dawley rats were used in these studies. Rats were 
purchased as middle-aged reproductive senescent females (retired breeders, 9–11 
months; weight range, 325–350 g) from Harlan Laboratories. The middle-aged females 
met our previously established criteria for reproductive senescence (Bake, et al. 2004; 
Jezierski, et al., 2001). Daily vaginal smears were performed to determine that all 
senescent females were acyclic and in constant diestrus for at least 2 weeks before the 
experiment. All animals were housed in an American Association for Laboratory Animal 
Care–approved facility, maintained on a constant photoperiod (12-hour light/dark 
cycles), and fed ad libitum with laboratory chow (Harlan Teklad 8604) and water. All 
animal procedures were performed in accordance with the National Institutes of Health 
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guidelines for the humane care of laboratory animals and were approved by the 
Institutional Animal Care Committee. 
2.3.1. Analysis of immune cell transfer to the brain post stroke  
 Surgical procedures 
Middle-aged Sprague-Dawley females were anesthetized (with xylazine and 
ketamine) and placed in a stereotaxic instrument (David Kopf Instruments). A 28-gauge 
cannula was implanted into the right lateral ventricle using the following coordinates: 
−1.0 mm posterior to bregma, −1.4 mm lateral, and −3.5 mm from dural surface, as 
described previously (Selvamani and Sohrahji, 2010; Bake, et al., 2014). The cannula 
was anchored in place with Loctite 454 (Braintree Scientific). Animals were allowed to 
recover for 1 week after cannula implantation to ensure that any local inflammation 
caused by its placement was abated by the time the stroke surgery was performed. 
2.3.2. Middle cerebral artery occlusion (MCAo) 
Rats were anesthetized and subjected to MCAo via intraluminal suture, using the 
procedures described previously (Bake, et al., 2014). The intraluminal suture was 
maintained for 90 minutes and then withdrawn. The tissue perfusion rate was monitored 
using laser Doppler flowmetry (Moor Instruments), and the perfusion index was 
calculated for both ischemic and reperfusion time points. MCAo resulted in an 80% 
reduction of blood flow compared with the preocclusion rate, and reperfusion restored 
the perfusion index back to preocclusion levels. An osmotic minipump (flow rate, 1 
μL/h, ALZET 1003D; Alzet Corp) filled with human recombinant IGF-I (100 μg/mL; 
R&D Laboratories) primed overnight was placed into a subcutaneous pocket between 
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the scapula and spine after 45 minutes of ischemia. Control animals were infused with 
artificial cerebrospinal fluid. 
2.3.3. Isolation of central nervous system infiltrates and staining 
Forty-eight hours after MCAo, animals were deeply anesthetized and perfused 
with saline. The brain was then removed and the ischemic and nonischemic cortices 
were dissected. Cortices were dissociated using a Neural Tissue Dissociation Kit 
(Miltenyi Biotech) and resuspended in X-VIVO-15 (Lonza). The homogenate was then 
layered on a Percoll gradient and centrifuged for 30 minutes at 500 × g at 4°C. Cells at 
the 70%–30% interphase were collected and resuspended in cell-staining buffer. The 
single-cell suspension was pipetted into 96-well plates, and the cells were counted on an 
automated cell counting apparatus (Countess; Life Technologies). Cells were washed 
with Flow Staining Buffer (eBioscience) and then incubated with anti-rat CD4-
fluorescein isothiocyanate (FITC) (1:200) or triple labeled with anti-rat CD4-FITC 
(1:200)/anti-rat CD25 (1:100)/anti-mouse FoxP3 (1:100) (Table 2-1). After staining for 
surface markers, cells were fixed and made permeable according to the manufacturer's 
instructions (BD Biosciences) before staining for the intracellular marker. For each 
animal, 3 technical replicates were prepared and phenotyped via a FACSAria flow 
cytometer (BD Biosciences) and analyzed with FlowJo software (Tree Star). 
The following gating strategy was used to identify CD4+ cells and regulatory T 
cells. Dead cells and debris were removed from analysis via forward scatter and side 
scatter. Only singlets were considered during analysis. To control the cellular 
autofluorescence, unstained samples (without dye-conjugated antibodies) were prepared. 
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For CD4+ cells, an initial gate was scaled where 99% of the unstained cells were 
excluded. For stained samples (samples that included dye-conjugated antibodies), any 
cells determined to be within the initial gate were considered positive. For T regulatory 
(Treg) cells, the quadrant system was created so that 99% of the unstained cells were in 
the third quadrant (quadrant 1, FoxP3+CD25−; quadrant 2, FoxP3+CD25+; quadrant 3, 
FoxP3−CD25−; and quadrant 4, FoxP3−CD25+). Only CD4+ cells from stained samples 
that were determined to be in quadrant 2 (FoxP3+CD25+) were considered Treg cells. 
The number of CD4+ or CD4/CD25/FoxP3+ cells in the ischemic hemisphere was 
normalized to the number in the nonischemic hemisphere. 
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Table 4-1 Continued 
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 Brain microvascular endothelial cell (BMEC) culture 
To harvest primary BMECs, the brain was removed from deeply anesthetized 
(xylazine [13 mg/kg] and ketamine [87 mg/kg]) animals. Meninges and macroscopic 
vessels were discarded, and cortical tissue was collected in ice-cold 1× PBS (dPBS; 
Invitrogen). Tissues were washed in sterile PBS (3×) and homogenized with 10 gentle 
strokes of a loose-fitting pestle of a Dounce homogenizer. The homogenate was spun at 
720 × g for 5 minutes at 4°C, and the pellet was suspended in PBS and layered over an 
equal volume of 18% dextran (Sigma-Aldrich). This mixture was spun at 3300 rpm for 1 
hour at 4°C in a swinging bucket rotor centrifuge. The resulting pellet was suspended 
again in PBS and was filtered sequentially through a 150-μm filter followed by a 70-μm 
filter. The microvessels were recovered and digested in collagenase-dispase (1 mg/mL) 
at 37°C for 15 minutes. The digested vessel/cell mixture was recovered in Hanks' 
balanced salt solution (Invitrogen) and centrifuged at 125 × g for 5 minutes, and the 
resulting pellet was suspended in endothelial growth media, containing phenol red–free 
Iscove's modified Dulbecco's medium (Invitrogen) supplemented with 10% heat-
inactivated fetal bovine serum (FBS) (Invitrogen), endothelial cell growth factor (25 
μg/mL: BD Biosciences), heparin (100 μg/mL; Sigma-Aldrich), and penicillin-
streptomycin (100 U/mL; Invitrogen, CA) and plated onto collagen IV (Sigma-Aldrich)–
coated dishes. Cultures were maintained at 37°C in a humidified atmosphere of 5% CO2-
95% O2 for 7 days and then were trypsinized and replated onto 60-mm culture dishes 
coated with collagen. 
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For subsequent assays, cells were plated in either 6- or 96-well dishes. For every 
assay, a single run consisted of cortical tissue pooled from 4 middle-aged (reproductive 
senescent) animals. Three such runs were performed for each assay. The cultures were 
passaged once before the experiment and were discarded after the experiment. 
2.3.4. Characterization of endothelial cell cultures 
Cells (harvested as described above) were grown on collagen-coated coverslips, 
fixed in 4% paraformaldehyde and processed for immunohistochemical analysis using 
primary antibodies for von Willebrand factor (vWF) (factor VIII), an endothelial cell 
marker (Labvision), and Alexa Fluor 594 secondary antibodies (Invitrogen). Cell 
cultures were also exposed to DiI-labeled acetylated low-density lipoprotein (Ac-LDL) 
(Sigma-Aldrich) in medium to detect Ac-LDL uptake. Cultures were also 
immunolabeled for glial fibrillary acidic protein (GFAP), an astrocytic marker 
(Millipore), ionized calcium-binding adaptor molecule 1 (Iba-1), a microglial marker 
(Abcam) and α-smooth muscle actin (Abcam), a marker for pericytes to determine the 
purity of endothelial cultures. Cells were counterstained with Hoechst dye for nuclear 
labeling. 
2.3.5. Oxygen-glucose deprivation (OGD) procedure 
Confluent cultures grown on 6-well culture plates were subject to hypoxia (1% 
O2, 95% N2, and 5% CO2) in glucose- and FBS-free media with or without IGF-I (10 
ng/mL). After 6 hours, the cultures were re-oxygenated in endothelial growth medium 
under normal conditions (5% CO2 and 95% O2). Medium was collected, and cells were 
photographed to record changes in cell morphology. 
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2.3.6. Lactate dehydrogenase (LDH) assay 
Cell death was estimated by LDH in medium immediately after collection 
(Roche Applied Science). In brief, 50 μL of culture medium was added to each well of a 
96-well plate and mixed with the catalyst and dye substrate mixture. After incubation for 
30 minutes, 50 μL of stop solution was added to each well, and the plate was read at 490 
nm absorbance on a plate reader (Tecan). 
2.3.7. In vitro permeability assay: FITC-BSA transfer assay 
Cells were plated at a density of 3 × 10 (4) onto collagen-coated inserts (0.4-μm 
pore size polycarbonate membrane; BD Biosciences) in FBS-free medium containing 
IGF-I or vehicle. After OGD and reoxygenation, FITC-BSA (250 μg/mL, 66 kDa; 
Sigma-Aldrich) was added to the medium in the top chamber. After 30 minutes, medium 
collected from the bottom chamber was loaded on a 96-well plate, and the plate was read 
at 492 nm (excitation)/520 nm (emission). Cells were stained with Hoechst dye and read 
at 350 nm (excitation)/420 nm (emission) and 492 nm (excitation)/520 nm (emission). 
2.3.8. Statistical analysis 
Group differences were analyzed by one-way ANOVA or paired t test using 
SPSS Statistic 20 software (IBM), and differences were considered significant at P < 
.05. For ex vivo cultures, 3 to 5 biological replicates were prepared, with 3 technical 
replicates per run. In each run, the normoxic group or the vehicle-treated group was set 





2.4.1. Effect of IGF-I on immune cell extravasation into the ischemic brain 
To determine the effect of IGF-I on brain extravasation of immune cells in 
middle-aged females, mononuclear cells, harvested from ischemic and nonischemic 
cortex, were stained for CD4, a surface marker for a broad range of immune cells 
including T helper cells, macrophages, monocytes, and dendritic cells. The ratio of CD4+ 
cells (ischemic/nonischemic hemisphere) was significantly reduced in IGF-I–treated 
animals compared with those in controls (Figure 2-1, A and B). In addition, cells were 
stained for CD4/CD25/FoxP3 to evaluate Treg cells. The ratio of this specific cohort of 
T cells was also significantly lower in IGF-I–treated groups than in vehicle-treated 
controls (Figure 2-1, C and D), suggesting that IGF-I reduces immune cell trafficking 







Figure 2-1: IGF-I regulates immune cell infiltration into ischemic cortex   
A, Transient ischemia (90 minutes)/reperfusion (48 hours) resulted in an increased 
proportion of CD4+ cells in the ischemic cortex of vehicle-treated middle-aged females 
(top left plot) compared with those of IGF-I–treated females (top right plot). B, IGF-I 
significantly reduced the ratio of CD4+ cells in the ischemic vs nonischemic hemisphere 
compared with those in vehicle-treated animals. C and D, the ratio of Treg cells (cells 
stained positive for CD4/CD25/FoxP3) was also significantly decreased in the IGF-I–
treated group compared with that in controls, suggesting IGF-I–mediated reduction in 




2.4.2. Characterization of primary BMECs cultures 
Primary BMECs derived from female rat microvessels (described above) were 
plated on collagen-coated coverslips and immunostained for vWF (factor VIII, which is 
found exclusively in endothelial cells. As shown in Figure 2ai, virtually all cells were 
immunopositive for vWF. No staining was visible in cultures that were processed in the 
absence of the primary antibody (Figure 2-2aii). In cultures exposed to DiI-labeled Ac-
LDL (which specifically identifies endothelial cells and macrophages), Ac-LDL uptake 
was seen in all cells (Figure 2-2aiii). Virtually no GFAP-positive (0%; Figure 2-2ci), 
Iba-1–positive (0%; Figure 2-2cii), or α-smooth muscle actin–positive (0.002%; Figure 
2ciii) cells were seen in these cultures, indicating that these cultures were largely free of 






Figure 2-2: Characterization of BMECs from adult rat brain cortex  
A, BMECs were immuno-labeled for the endothelial marker factor VIII (vWF). Virtually 
all cells were immunopositive for factor VII (red; ai), whereas no label was seen in 
cultures in which the primary antibody was omitted (aii). BMECs were counterstained 
with the nuclear dye, Hoechst dye, seen in blue. B, Cultures were exposed to 
fluorescence-labeled Ac-LDL in medium, which was internalized by all cells, and is 
visible here as red punctate labeling. C, BMECs were not immunopositive for the 
astrocytic marker GFAP (ci) or the microglial marker Iba-1 (cii), although <0.002% cells 
were positively labeled for α-smooth muscle actin, a pericyte marker (ciii). Cells were 




2.4.3. OGD and reoxygenation cause cellular damage in middle-aged BMECs 
To determine the impact of stroke-like conditions on aging endothelial cells, 
confluent monolayers of middle-aged derived BMECs were exposed to several 
combinations of oxygen deprivation and aglycemia. The most consistent results were 
obtained using 6 hours of OGD (1% O2 and aglycemic medium) followed by 3 hours of 
reoxygenation in defined medium without FBS, and these conditions were used in all 
subsequent experiments. As shown in Figure 2-3, compared with normoxic controls 
(Figure 2-3ai), OGD caused visible changes to the morphology of BMECs (Figure 2-
3aii). These included elongation and shrinkage of the cell body, resulting in fewer cell-
cell contacts. In contrast, IGF-I–treated cultures showed reduced cell density, but cell 
bodies were not as elongated and cell-cell contacts were clearly visible (Figure 2-3aiii). 
After reoxygenation, BMECs still exhibited shrunken cytoplasmic profiles with reduced 
cell-cell contact (Figure 2-3av) compared with normoxic cells (Figure 2-3aiv), whereas 
IGF-I–treated cultures continued to show better cell-cell contacts (Figure 2-3avi). 
Medium LDH levels were used to estimate OGD-induced cytotoxicity. LDH 
levels were increased more than 2-fold in cultures exposed to OGD as compared to 
normoxic controls, and IGF-I treatment did not affect LDH levels (Figure 2-3B). The 
medium replaced after OGD and collected 3 hours later had similar levels of LDH with 





Figure 2-3: Effect of OGD, OGD and reoxygenation, and IGF-I on BMECs from 
middle-aged females  
A, Compared with normoxic controls (ai), OGD resulted in morphological changes in 
endothelial cells including cell elongation, shrunken cell profiles, and reduced 
intercellular contact (aii). IGF-I–treated cultures showed less cellular elongation and 
fewer intercellular spaces indicating, greater cell-cell communication after OGD (aiii). 
Reoxygenation did not improve cell morphology and cell contacts in either untreated 
(av) or IGF-I–treated cultures (avi). B, LDH was measured in BMEC cultures exposed to 
IGF-I or vehicle after OGD and OGD and reoxygenation (Re-OX). OGD significantly 
increased medium LDH levels. However, IGF-I did not attenuate OGD-induced increase 
in LDH levels. LDH levels after reoxygenation were no different in vehicle and IGF-I–
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treated cultures. The data shown represent 3 separate runs, with each run consisting of 
cells derived from 4 animals. *, P < .05 (compared to normoxia). Bar, 50 μm. 
2.4.4. Effect of IGF-I on permeability of BMEC monolayers exposed to OGD 
reoxygenation 
Our previous in vivo data showed that IGF-I reduced extravasation of Evans blue 
dye (18), a compound that binds serum albumin. Thus, to facilitate comparisons with the 
in vivo data, FITC-labeled albumin (FITC-BSA; 66 kDa) was used in these studies. 
BMEC cultures, treated with IGF-I or vehicle, were exposed to OGD reoxygenation. 
FITC-BSA was then added to the medium in the top chamber. IGF-I–treated cultures 
showed significantly lower levels of FITC-BSA in medium collected from the bottom 
chamber. In comparison to control-treated cultures, FITC-BSA transfer was reduced by 
30% in IGF-I–treated cultures (P < .05) (Figure 2-4A). 
Because BSA is also transferred by receptor-mediated transcytosis (27–29), 
FITC-BSA accumulation was also estimated in the BMEC monolayer. IGF-I–treated 
cultures had significant reductions in FITC-BSA (normalized to Hoechst dye 
measurement), indicating that IGF-I reduced the cellular uptake of FITC-BSA compared 




Figure 2-4: OGD and reoxygenation induced changes in barrier properties of 
endothelial cells  
A, OGD induced changes in FITC-BSA transfer: FITC-BSA transport was measured 
across the monolayer of cells after OGD and reoxygenation. FITC-BSA transfer was 
significantly lower in cultures treated with IGF-I compared with vehicle treatment. B, 
FITC-BSA in the endothelial monolayer was normalized to nuclear dye (Hoechst) to 
determine the extent of BSA that was internalized by endothelial cells. There was a 50% 
decrease in the FITC-BSA/Hoechst ratio in IGF-I–treated cultures, suggesting reduced 
cellular uptake compared with that for vehicle treatment. The data represent the average 
from 3 independent runs, each run consisting of cells derived from 4 middle-aged 




The present data show that poststroke IGF-I treatment reduces extravasation of 
immune cells into the ischemic cortex of middle-aged female rats. IGF-I also acts 
directly on aging endothelial cells to reduce protein transfer in an ex vivo model. In 
conjunction with our previous studies showing that IGF-I reduces transfer of Evans dye 
to the ischemic hemisphere (Bake, et al., 2014), the present study supports the 
hypothesis that immune cell extravasation is also greatly reduced by IGF-I treatment and 
provides direct evidence that IGF-I improves the barrier properties of the aging 
endothelial cell. 
Poststroke inflammation plays a central role in stroke pathology (Samson, et al., 
2005), and infiltration of immune cells into the ischemic central nervous system has 
been documented in a variety of experimental models (Jin, et al., 2010; Huang, et al., 
2006; Banerjee, et al., 2013). T and B cells, macrophages, and natural killer cells are 
shown to invade the ischemic brain in the acute phase of stroke. T-cell infiltration is 
detrimental during the early phase of ischemic brain injury (Ren, et al., 2011; Gu, et al., 
2015), and depletion of T and B cells is shown to reduce the cortical infarct volume at 22 
hours poststroke (Hurn, et al., 2007). Blocking of T-cell function with recombinant T-
cell receptor ligand RTL1000 attenuates inflammation and improves infarct size in 
middle-aged mice (Subramanian, et al., 2009, Zhu, et al. 2015). The role of Treg cells in 
stroke is controversial. Liesz et al. (2009) have shown that Treg cell depletion increases 
infarct volume, whereas another study using an alternative approach to deplete Treg cells 
showed no effect on infarct volume (Ren, et al., 2011). Furthermore, selective depletion 
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of Treg cells significantly reduced infarct volume and improved neurological function 
(Kleinschnitz, et al., 2013), whereas adoptive transfer of Treg cells protected against 
ischemia. In the present study, decreased Treg cell proportions in IGF-I–treated animals 
may suggest that decreased Treg cell function is associated with better stroke recovery. 
The fact that IGF-I decreased generic CD4+ cells, which represent a wide range of 
immune cells, supports the alternate explanation that IGF-I blocks their passage across 
the blood-brain barrier. This is further supported by the ex vivo data showing that IGF-I 
treatment reduced transfer of FITC-BSA across the endothelial monolayer. 
Most studies in the literature show that IGF-I is a proangiogenic growth factor. 
Age-related change in cerebral microvessel density is correlated with changes in GH and 
IGF-I, and GH treatment, which up-regulates IGF-I, increases cortical vascular density 
in older animals (Sonntag, et al., 1997). In adult animals, systemic IGF-I infusion 
promotes brain vessel formation (Lopez-Lopez, et al., 2004). IGF-I is also implicated in 
retinal vascularization in humans (Hellström, et al., 2002) and mice (Smith, et al., 1999). 
In the present study, IGF-I did not reduce cell death (as measured by LDH) in aging 
endothelial cells, although IGF-I may increase proliferation in these cells over the long 
term. 
Although the effect of IGF-I on cerebral microvasculature is well known, the 
effect of IGF-I on blood-brain barrier permeability is less studied and more 
controversial. In the spinal cord, topical applications of IGF-I at high doses reduced the 
breakdown of the blood-spinal cord barrier, reduced spinal edema, and improved axonal 
repair in a traumatic injury to the T10–T11 segments (Sharma, et al., 2005). Low-dose 
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IGF-I was ineffective for all these measures. In an acute demyelinating experimental 
autoimmune encephalomyelitis (EAE) model of multiple sclerosis, intravenous IGF-I 
given over 8 days reduced permeability of the blood-spinal cord barrier and improved 
motor outcomes. Here also, high doses of IGF-I were more effective than low doses 
(Liu, et al., 1995). However, other evidence indicates that IGF-I treatment in an acute 
inflammatory condition may actually increase blood-brain barrier permeability. 
Intraventricular injections of lipopolysaccharide in a neonatal rat, which is an 
experimental model of periventricular leukomalacia, cause rapid dysregulation of the 
blood-brain barrier, activation of microglia and astrocytes, and recruitment of leukocytes 
to the brain. Low-dose IGF-I treatment in this model prevented cell death associated 
with this injury. However, IGF-I also increased the permeability of the blood-brain 
barrier and recruitment of leukocytes and caused intracerebral hemorrhage (Pang, et al., 
2010). High doses of IGF-I in conjunction with LPS increased mortality, indicating that 
the peptide hormone may have anomalous effects in acute inflammation. Cerebral edema 
due to cirrhotic liver disease and portal vein occlusion was not improved by IGF-I 
treatment (Odena, et al., 2012). In fact, in peripheral tissues, IGF-I treatment is known to 
cause mild generalized and reversible edema. In a small study with 8 healthy 
participants, IGF-I treatment resulted in greater vascular permeability in skin and retina 
than in controls (Hussain, et al., 1995). In contrast, IGF-I preserved barrier properties in 




Neuroprotective strategies have been largely neuron-centric, and clinical trials 
and experimental stroke studies in which the primary therapeutic focus is the rescue of 
neurons are only partly successful (Berezowski, et al., 2012; Lo, et al., 2004). 
Experimental and clinical studies have repeatedly shown that microvascular dysfunction 
is a critical factor for neuronal death during the early phase of ischemia-reperfusion 
injury (del Zoppo, et al., 1994; Gursoy-Ozdemir, et al., 2012; Kaur, et al., 2011), and 
accumulating evidence suggests that brain microvessels play an important role in the 
clinical outcome of stroke patients. The present studies implicate the microvasculature as 
a target for stroke therapies in middle-aged females. 
2.6. Abbreviations 
The following abbreviations were used in the First Study:   
ac-LPL: acetylated low-density lipoprotein 
BMEC: brain microvascular endothelial cell 
FBS: fetal bovine serum 
FITC: fluorescein isothiocyanate 
GFAP: glial fibrillary acidic protein 
Iba-1: ionized calcium-binding adaptor molecule 1 
LDH: lactate dehydrogenase 
MCAo: middle cerebral artery occlusion 
OGD: oxygen-glucose deficiency 
Treg: T regulatory 
vWF: Von Willebrand factor. 
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3. SECOND STUDY: INSULIN-LIKE GROWTH FACTOR (IGF)-1 TREATMENT 
STABILIZES THE MICROVASCULAR CYTOSKELETON UNDER ISCHEMIC 
CONDITIONS2 
 
3.1. Overview of the Second Study 
Our previous studies showed that Insulin-like Growth Factor (IGF)-1 reduced 
blood brain barrier permeability and decreased infarct volume caused by middle cerebral 
artery occlusion (MCAo) in middle aged female rats. Similarly, cultures of primary brain 
microvessel endothelial cells from middle-aged female rats and exposed to stroke-like 
conditions (oxygen glucose deprivation; OGD) conﬁrmed that IGF-1 reduced dye 
transfer across this cell monolayer. Surprisingly, IGF-1 did not attenuate endothelial cell 
death caused by OGD. To reconcile these ﬁndings, the present study tested the 
hypothesis that, at the earliest phase of ischemia, IGF-1 promotes barrier function by 
increasing anchorage and stabilizing cell geometry of surviving endothelial cells. 
Cultures of human brain microvessel endothelial cells were subject to oxygen-glucose 
deprivation (OGD) in the presence of IGF-1, IGF-1+JB-1 (IGFR inhibitor) or vehicle. 
OGD disrupted the cell monolayer and reduced cell-cell interactions, which was 
preserved in IGF-1-treated cultures and reversed by concurrent treatment with JB-1. 
IGF-1-mediated preservation of the endothelial monolayer was reversed with LY294002 
                                                 
2 Reprinted with permission from Bake S, Okoreeh A, Khosravian H, Sohrabji F. Insulin-
like Growth Factor (IGF)-1 treatment stabilizes the microvascular cytoskeleton under 
ischemic conditions. Exp Neurol. 2019 Jan.;311:162-172. 
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treatment, but not by Rapamycin, indicating that IGF-1s actions on cell-cell contacts are 
likely mediated via the PI3K pathway. In vivo, microvessel morphology was evaluated 
in middle-aged female rats that were subjected to ischemia by MCAo, and treated ICV 
with IGF-I, IGF-1+JB-1, or artiﬁcial CSF (aCSF; vehicle) after reperfusion. Compared 
to vehicle controls, IGF-1 treated animals displayed larger microvessel diameters in the 
peri-infarct area and increased staining density for vinculin, an anchorage protein. Both 
these measures were reversed by concurrent IGF-1+JB-1 treatment. Moreover these 
eﬀects were restricted to 24h after ischemia-reperfusion and no treatment eﬀects were 
seen at 5d post stroke. Collectively, these data suggest that in the earliest hours during 
ischemia, IGF-1 promotes receptor-mediated anchorage of endothelial cells, and its 
actions may be accurately characterized as vasculoprotective. 
3.2. Introduction 
Ischemic stroke causes loss of nutrients to brain tissue and initiates a sequence of 
harmful events within neurons including rapid failure of ATP-dependent processes, 
increased release of glutamate and calcium, and rapid cell death (Pulsinelli, 1992; 
Moskowitz et al., 2010; Khatri et al., 2012). The earliest impact of ischemia includes 
changes in the blood brain barrier, followed by vasogenic edema in the brain (Yang et 
al., 2007). These deleterious changes to the barrier are accompanied by disruption of 
intercellular tight junction assembly causing microvessel hyperpermeability (Kreuger 
and Phillipson, 2016), heightened inflammatory responses (Gidday et al., 2005; 
Kleinschnitz and Wiendl, 2013) and loss of anchorage of endothelial cells (Baldo et al., 
2015). Cell surface alterations on the endothelium such as the upregulation of adhesion 
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molecules ICAM-1 and CCL2 facilitates infiltration of neutrophils and macrophages into 
the brain during the early phase of injury (Dimitrijevic et al., 2007; Wu et al., 2015; Shi 
et al., 2016; Zhu et al., 2016). Blood brain barrier hyperpermeability and edema is 
associated with poor prognosis (Khatri et al., 2012), and consistent with this observation, 
stroke-induced brain damage and disability and blood-brain barrier permeability is 
significantly higher in older animals as compared to young animals (Dinapoli et al., 
2008; Liu et al., 2009; Montagne et al., 2015). Hence, the blood brain barrier and its 
component cells are critical for stroke pathophysiology and are considered important 
targets for stroke therapy (Borlongan et al., 2012; Merali et al., 2016) 
Our previous studies show that middle-aged female rats sustain larger infarcts 
and worse stroke outcomes as compared to younger females (Selvamani and Sohrabji, 
2010a, Selvamani and Sohrabji, 2010b), and this is associated with decreased levels of 
circulating and parenchymal IGF-1. Accordingly, intracerebroventricular (ICV) delivery 
of IGF-1 2 h after ischemia to middle-aged female rats reduces infarct volume when 
measured 24 h after stroke. In silico analysis of epigenetic modulators indicated that 
IGF-1 regulated microRNAs that improve extracellular matrix interactions and 
endothelial cells. We focused on blood brain barrier changes and reported that as early as 
4 h after MCAo, IGF-1 treatment decreased blood brain barrier permeability to small 
molecules (Bake et al., 2014) although the peptide did not reduce infarct volume at this 
time point. At 48 h after MCAo, when brain trafficking of T-regulatory cells was seen, 
IGF-1 reduced passage of these larger elements as well (Bake et al., 2014; Bake et al., 
2016). Ex vivo cultures of primary brain microvascular endothelial cells (BMECs) from 
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middle-aged rats subject to OGD showed that IGF-1 reduced transfer of FITC-BSA 
transfer across the monolayer (Bake et al., 2016), but did not prevent cell death. These 
data suggest that IGF-1 actions during the earliest phase of ischemia are not dependent 
on cell survival, but may act via a different mechanism. The present study employed 
complementary in vivo and in vitro approaches to test whether IGF-1 prevents ischemia-
induced cytoskeletal rearrangement and cell detachment from the extracellular matrix. 
3.3. Materials and Methods  
3.3.1. In vitro studies 
 Cell culture and oxygen glucose deprivation (OGD) 
Human brain microvascular endothelial cells (hBMEC) were purchased from 
Millipore Corp. MA (hCMEC/D3,) and grown with EndoGro medium (Millipore Corp. 
MA) on type I collagen-coated T-75 flasks. For experiments, cells (5 × 104) were plated 
either on collagen-coated coverslips or in 96-well plates and maintained until confluent. 
Cultures were grown in normoxic conditions (5% CO2 and 21% O2; 37 °C) until 
confluent. Cells were then subject to OGD (1% O2, 95% N2 and 5% CO2 in glucose 
free DMEM) for 6 h with IGF-1 (10 ng/ml), IGF-1 + JB-1 (IGF-1 receptor antagonist; 
2 ng/ml), IGF1+ LY294002 (reversible PI3-kinase inhibitor, 1 μg/ml) and rapamycin 
(mTOR inhibitor, 1μg/ml) or vehicle (PBS or DMSO). Culture media was collected for 
assays and cells were fixed for histological analysis. All assays were conducted with 3–5 




 Quantitative (q)RT-PCR 
Human IGF1R mRNA expression in hBMEC was assessed using real-time qRT-
PCR. Total RNA was extracted using QIAzol reagent and RNA Mini extraction kit 
(Qiagen, CA) using our previous procedures (Okoreeh et al., 2017). RNA yield and 
purity were evaluated with a NanoDrop ND-1000 spectrophotometer (NanoDrop 
Technologies/Thermo Scientific). 100 ng of purified total RNA was used to generate 
cDNA, using a cDNA Synthesis Kit (Quantbio, MA) following manufacturer's protocol. 
cDNA was diluted 80 fold and real time PCR reaction were run on Applied Biosystems 
7900HT real-time PCR instrument (Applied Biosystems, CA) using a SYBR green-
based real-time PCR reaction kit (Quantabio, MA). 18 s mRNA was used as a 
normalization control. Human IGF-1R (Forward:5′- TTA AGA ACC AGT GGC GAA 
AG -3′, Reverse: 5′- GGA GCA CTC ACT TCT CCA AA -3′ Realtime primers, PA) and 
18S primers (Forward:%’-ATGGCCGTTCTTAGTTGGTG -3′; Reverse: 5′-
CGCTGAGCCAGTCAGTGTAG-3′, Life Technologies, CA). 
 Cell death/survival assays 
3.3.1.3.1. LDH assay 
Cell death was estimated by lactate dehydrogenase (LDH) in media immediately 
after collection, using a colorimetric assay (Thermofisher, MA) and our previous 
procedures (Bake et al., 2016). Briefly, 50 μl of culture media was added to each well of 
a 96-well plate and mixed with catalyst and dye substrate mixture. After incubation for 
30 min, 50 μl of stop solution was added to each well and the plate was read at 490 nm 
absorbance on a colorometric plate reader (Tecan, Switzerland). Calcein assay: Cell 
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viability was determined using the Calcein-AM dye (Life Technologies,CA). After 
OGD, cells were incubated with calcein-AM (2.5 μm) in PBS for 20 min at 37 °C and the 
fluorescence was measured on a plate reader (Tecan, Switzerland) with excitation/ 
emission set at 480 and 530 nm respectively. 
3.3.1.3.2. Phalloidin staining 
Endothelial cells grown on coverslips were washed and fixed with 4% 
paraformaldehyde, and then permeabilized in 0.1% triton-X and washed three times with 
PBS. Cells were then incubated with 3% BSA for 20 min followed by two washes and 
stained with Alexa Fluor 488 phalloidin (Life technologies, CA) for 30 min, washed with 
PBS and mounted with Prolong antifade mounting media (Life technologies, CA). 
Images were captured on the FSX100 Olympus microscope. 
3.3.1.3.3. Vinculin immunohistochemistry 
Endothelial cells grown on coverslips were processed for immunohistochemistry 
using our previously published procedures (Bake et al., 2016). Briefly, cells were 
incubated in a blocking solution (2% normal goat serum and 2% triton X-100 in dPBS) 
for 1 h at room temperature, followed by incubation with the antibody for vinculin 
(eBioscience, San Diego, CA, 1:100) overnight. Following 3 PBS washes, cells were 
then incubated for 1 h with fluorescent-labeled secondary antibody (Alexa Fluor 594 
goat anti-mouse, 1:500 dilution) and were counterstained with nuclear dye (Hoechst, 
1:500) and coverslipped with Prolong antifade mounting media (Life technologies, CA). 




3.3.1.3.4. Lectin staining 
In vitro analysis: Endothelial cells grown on coverslips were washed and fixed 
with 4% paraformaldehyde, and then permeabilized in 0.1% triton-X and washed three 
times with PBS. Cells were then incubated with 3% BSA for 20 min followed by two 
washes and stained with lectin (1:1000, Vector Laboratories, CA) for 30 min, washed 
with PBS and mounted with Prolong antifade mounting media. Images were captured on 
the FSX100 Olympus microscope. Determination of intercellular spaces: Lectin-stained 
cell cultures (3 experimental replicates) were photographed, coded and analyzed for 
continuity of the monolayer using a novel algorithm to determine intercellular ‘spaces’. 
Briefly, all images were first converted into grayscale images. A threshold was 
calibrated for each image to convert the grayscale image into a black and white one, 
such that cells are in white and everything else remains black. Thus, the total number of 
gaps between cells in each image was estimated by the total number of black pixels. 
Once the cells were identified, the two images were overlaid to find all the cells and the 
near empty areas in the image. The spaces near cells were calculated using the Canny 
edge detection algorithm. The above algorithm was coded in Python and OpenCV. 
3.3.2.  In vivo studies 
 Animals 
Female Sprague Dawley (SD) rats were purchased as retired breeders (10–
12 months; weight range 325–350 g) from Envigo Laboratories (previously Harlan Labs, 
IN). This group met our previously established criteria for reproductive senescence, 
namely, at least five successful pregnancies and current acyclicity determined by daily 
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vaginal smears. All animals were housed in an AAALAC–approved facility, maintained 
on a constant photoperiod (12-h light/dark cycles), and fed ad libitum with laboratory 
chow (Harlan Teklad 8604) and water. All animal procedures were performed in 
accordance with the National Institutes of Health guidelines for the humane care of 
laboratory animals and were approved by the Institutional Animal Care Committee and 
the Institutional Biosafety Committee. A total of 55 animals were used in this study, 
with 7–9 animals per group for behavioral analysis and 5–6 animals per group for 
histological analysis. 
  Surgical procedures 
3.3.2.2.1. Cannula implantation 
Animals were placed in a stereotaxic instrument (David Kopf instruments, CA), a 
28 gauge cannula was implanted into the right lateral ventricle using the co-ordinates – 
1.0 mm posterior to bregma, −1.4 mm medial lateral, −3.5 mm from dural surface, and 
anchored in place with loctite 454 (Braintree Scientific, MA). Animals were allowed to 
recover for 1 week following cannula implantation and prior to stroke surgery. Alzet 
osmotic minipumps (1003D & 1007D, Alzet corp., CA, flow rate 0.5 and 1 μl/h) filled 
with human recombinant (rh)IGF-1 (R&D Laboratories, 100 μg/ml) or rhIGF-1 and JB-1 
(20 μg/ml) were primed overnight and placed into a subcutaneous pocket between the 
scapula and spine, after 45 min of ischemia. IGF-1 delivery to the brain initiated 2 h after 
the onset of ischemia. Previous studies have shown that IGF-1 is stable in Alzet 
minipumps for up to 7 days. Control animals were infused with artificial CSF. All 
animals were terminated either 1 day or 5 days post-reperfusion. 
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3.3.2.2.2. Middle cerebral artery occlusion (MCAo) 
Animals were subjected to middle cerebral artery occlusion (MCAo) via 
intraluminal suture 1 week after cannula implantation, using our previous procedures 
(Bake et al., 2014; Bake et al., 2016). Briefly, rats were anesthetized with isoflurane and 
maintained at 37 °C on heating pads in dorsal recumbency. The neck region was shaved 
and disinfected and a ventral midline incision was made on the skin. Superficial fascia 
on the right side of the neck was dissected and the underlying muscles were blunt 
dissected to expose the right common carotid (CCA), external (ECA), and internal 
carotid (ICA) arteries. The ECA was separated from the vagus nerve and tied off distally 
with silk sutures after cauterizing the small branches. Microsurgical clamps were placed 
on CCA and ICA. A loose tie was placed on the ECA, and the free stump of ECA was 
aligned with the ICA. 22 mm of suture of the appropriate size (37–41) with a silicon-
coated round tip (Doccol Corp., CA) was inserted into ICA lumen through a small nick 
on the ECA between the two ties. The suture was advanced along the ICA until it 
reached the origin of the MCA (∼20 mm of suture) and secured in position with nylon 
ties. The intraluminal suture was maintained for 90 min and then withdrawn. Tissue 
perfusion rate was monitored using Laser-Doppler Flowmetry (Moor Instruments, UK) 
and the perfusion index was calculated for both ischemic and reperfusion time points. 
MCAo resulted in an 80% reduction of blood flow compared to the pre-occlusion rate 
and re-perfusion restored the perfusion index back to pre-occlusion levels. All animals 




 Behavioral analysis 
3.3.2.3.1. Neurological score 
Functional tests were performed 1 day after MCAo. Each animal underwent five 
tests in succession to assess motility, grasping, righting reflex, forepaw disability, and 
circling, as described in (Bake et al., 2016; Okoreeh et al., 2017). For each test, a higher 
score indicates a more severe deficit. 
3.3.2.3.2. Histological analyses 
Animals were deeply anesthetized with ketamine/xylazine (ketamine: 87 mg/kg; 
xylazine: 13 mg/kg) and then perfused transcardially with saline followed by a perfusion 
fix solution (4% paraformaldehyde, 4% sucrose in dPBS) and decapitated. Heads were 
placed in a container filled with perfusion fix solution overnight at room temperature. 
Subsequently, the brains were removed from the cranial vault and stored in Dulbecco's 
phosphate saline with 0.01% sodium azide until shipped to Neuroscience Associates 
(NSA, Nashville, TN) for processing. Briefly, brains were block embedded in 
MultiBrain® blocks and freeze-sectioned at 40 μm with a sliding microtome, yielding 
free-floating sections collected in antigen preservation solution. 
3.3.2.3.3. Vinculin immunohistochemistry 
Brain sections (40 μm) containing cortex and striatum were mounted and adhered 
to gelatin-coated glass slides and processed for vinculin immunohistochemistry as 
described above and analyzed as follows. Three images were captured from the peri-
infarct zone of the cortex and striatum of the immunostained section for each animal, 
using a Q-color camera attached to the FSX100 Olympus microscope. The section was 
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at the interaural level 8.7 mm, bregma −0.30 mm (Paxinos and Watson, 1986). 
Photomicrographs were coded and then analyzed for vinculin staining density using 
ImageJ software (NIH, MD). In each image, three regions were demarcated and the area 
occupied by vinculin particles were measured in each region. The area occupied by 
vinculin particles was then normalized to the area of the box to obtain the density of 
vinculin label. For each animal, density measurements were obtained separately for the 
cortex and striatum and then combined to obtain a single value for each animal. Both the 
ischemic and non-ischemic hemispheres were analyzed. Data was decoded and analyzed 
by 2 way ANOVA coded for hemisphere (repeated measure) and treatment condition. 
Separate analyses were performed for day 1 and day 5 post stroke (SPSS, IBM). 
3.3.2.3.4. Lectin 
Brain sections (40 μm) were mounted and adhered to gelatin-coated glass slides 
and stained for lectin as described above. Lectin-stained vessels were analyzed in the 
following way. Three images were captured each from the cortex and striatum of the 
immunostained section for each animal, using a Q-color camera attached to the FSX100 
Olympus microscope. The section was at the interaural level 8.7 mm, bregma −0.30 mm 
(Paxinos and Watson, 1986). Images were coded and processed in Autoquant X3 
(Mediacybernetics,US) and were analyzed for diameter and length of microvessels with 
Imaris (Bitplane, US). For each animal, values were obtained separately for the cortex 
and striatum and then combined and binned into 3 groups, 1-5 um, 6–10 um, 11+ um. 
Data was decoded and analyzed by 2 way ANOVA coded for treatment condition and 
bin (repeated measure). Due to the volume of data and the possibility of spurious errors, 
 71 
 
separate analyses were performed for each hemisphere and for day 1 and day 5 post 
stroke (SPSS, IBM). 
3.3.3. Statistical analysis 
Group differences were analyzed using SPSS Statistic 23 software (IBM) and 
differences were considered significant at p < 0.05. For in vitro studies, 3 to 4 biological 
replicates were prepared with 6 technical replicates per run. Each run was normalized to 
its normoxic control group and one way ANOVA was used to evaluate group 
differences, with planned comparisons. For in vivo studies, neurological scores were 
analyzed by one way ANOVA. Vinculin and lectin histology was analyzed as described 
above. Data are expressed as mean ± SEM. 
3.4. Results 
3.4.1. IGF-1 does not reduce OGD-induced cell death 
Media LDH from normoxic cultures and cultures exposed to OGD, with various 
treatments, was used as a surrogate marker for cytotoxicity (Figure 3-1A). Groups were 
compared using a one-way ANOVA with planned post hoc comparisons (F(5,18): 2.56, 
p = 0.084). Compared to normoxia, LDH levels were significantly elevated by 6 h of 
OGD (p = 0.045). Neither IGF-1 (p = 0.46) nor concurrent IGF-1 + JB-1 (p = 0.37) 
reduced LDH release under OGD conditions. Similarly, LY294002 (p = 0.94) or 
Rapamycin (p = 0.55) also did not reduce OGD induced levels of LDH. In addition, cell 
survival was also determined by the calcein-AM assay (Figure 3-1B), using a one way 
ANOVA and planned post hoc comparisons (F(5,17):2.73; p = 0.077). OGD 
significantly decreased cell survival as measured by calcein (p = 0.017). Here also IGF-1 
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treatment (p = 0.67), with and without Rapamycin (p = 0.83), or LY294002 (p = 0.56) did 
not improve cell survival. Collectively, these studies confirm that IGF-1 does not reduce 
cell death in the ongoing ischemic environment. Expression of IGF1R in hBMECs were 
confirmed with qRT-PCR and did not show any difference between normoxia and OGD. 
 
 
Figure 3-1: Graphical Representation of the Effect of IGF-1 on hBMECs cell 
adhesion and cytoskeletal organization. 
Compared to normoxic conditions (A and B), cultures exposed to OGD show retracted 
cells with low vinculin labeling (C) and bright stress fibers (green phalloidin, D). IGF-1-
treated cells displayed flattened cell morphology, similar to normoxic conditions, with 
brighter vinculin staining both in the cytoplasm and at the cell perimeter (E), with fewer 
stress fibers compared to OGD (F), while this pattern was reversed in cells treated 




3.4.2. IGF-1 preserved the actin cytoskeleton of human brain microvascular 
endothelial cells after OGD 
To determine whether IGF-1 improved endothelial cytoskeletal organization and 
cell adherence under OGD, cells were probed for phalloidin (actin) and vinculin, a 
membrane-cytoskeletal protein associated with cell-cell and cell-matrix junctions. 
Normoxic cells displayed either round or flattened profiles, with actin staining (in green, 
Figure 3-2B) localized to the edges of the cell (circular actin). While flattened cells 
displayed pale phalloidin staining, vinculin labeling (shown in red; Figure 3-2A) was 
seen in the cytoplasm as well as at the cell perimeter. Oxygen-glucose deprivation 
(OGD) visibly decreased cell density and caused cytoskeletal reorganization of surviving 
cells. Thick, brightly stained stress fibers (in green) can be seen in cells that are 
elongated (Figure 3-2C,) and with decreased vinculin staining. Under the same 
conditions, cells treated with IGF-1 showed flattened cell morphology with bright 
vinculin labeling in the cytoplasm and at the edges (Figure 3-2E) with reduced density of 
polymerized actin across the cells (Figure 3-2F). This pattern was reversed by concurrent 
treatment with JB-1. Cells treated concurrently with IGF-1 + JB-1 closely resembled the 
OGD treated cultures in the pattern of brightly stained stress fibers with more retraction 
of actin and diffuse vinculin labeling (Figure 3-2 G and H) indicating a receptor-





Figure 3-2: Cytology of the Effect of IGF-1 on hBMECs cell adhesion and 
cytoskeletal organization. 
Compared to normoxic conditions (A and B), cultures exposed to OGD show retracted 
cells with low vinculin labeling (C) and bright stress fibers (green phalloidin, D). IGF-1-
treated cells displayed flattened cell morphology, similar to normoxic conditions, with 
brighter vinculin staining both in the cytoplasm and at the cell perimeter (E), with fewer 
stress fibers compared to OGD (F), while this pattern was reversed in cells treated 
concurrently with IGF-1 + JB-1 (G&H). Bar: 50 um. 
To quantify the extent of OGD-dependent retraction of the endothelial cell 
monolayer, cultures were stained with lectin (Figure 3-3Ai). Lectin staining further 
confirmed that oxygen glucose deprivation caused significant retraction of cells resulting 
in discontinuous aggregates of small groups of cells. This pattern was quantified using a 
novel algorithm that calculates intercellular (IC) spaces (Figure 3-3Aii). This analysis 
showed an overall affect of OGD and IGF-1 on interceullar spaces (F(3,12): 5.864, 
p = 0.020). Specifically, OGD increased intercellular spaces as compared to normoxia 
(p = 0.017), while IGF-1 treatment reduced cell shrinkage due to OGD, and was no 
different from normoxia (p = 0.226). IGF-1 effects were reversed in cultures 
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concurrently exposed to IGF-1 + JB1 (p = 0.004, compared to normoxia). Quantitation of 
the intercellular gaps (Figure 3-3Bii) also confirmed that IGF-1 signaling inhibitors had 
distinct effects on IC spaces (F (5,12): 4.99, p = 0.01). Thus while OGD and OGD 
(vehicle control or DMSO) caused a > 5 fold increase in intercellular spaces as compared 
to normoxic cultures (p = 0.001), this was reversed by. IGF1 (p > 0.05). The effect of 
IGF-1 on IC spaces was abrogated by concurrent treatment with LY294002 (p = 0.020 
compared to normoxia), but not Rapamycin (p = 0.277) compared to normoxia), 
indicating that IGF-1 actions on the endothelial monolayer are mediated by PI3K but not 
the mTOR pathway. 
3.4.3. Impact of IGF-1 on microvessel architecture in vivo 
To determine if IGF-1 acts on microvessel anchorage and morphology in vivo, 
middle-aged female rats were subject to MCAo for 90 mins and treated with IGF-1 or 
IGF-1 + JB-1 or aCSF (vehicle) 2 h after the onset of ischemia. Neurological score, an 
assessment of motor function, was performed 24 h after reperfusion by an investigator 
(AO) blind to the treatment conditions. Vehicle-treated controls had a high mean score 
(4.28) indicative of greater disability, as compared to IGF-1-treated animals (2.5) 
(p = 0.0477) (Figure 3-4). In contrast, animals that received concurrent IGF-1 + JB-1 
performed as poorly (3.9), as the vehicle-treated controls (p = 0.612) and were 
significantly higher than animals which received IGF-1 only (p = 0.016), indicating that 





Figure 3-3: Lectin staining of human brain microvessel endothelial cells (hBMEC) 
under normoxic and OGD conditions  
 
Ai. Effect of IGF-1 and its receptor antagonist on intercellular spaces: Photomicrographs 
of lectin-stained cultures show that the even, confluent monolayer seen in normoxia is 
changed under OGD to smaller, densely-stained cells with large intercellular spaces. 
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Intercellular spaces were completely abrogated in IGF-1 treated cultures and this was 
reversed with concurrent exposure to JB-1. Aii Histogram shows average intercellular 
space estimates using the Canny Edge algorithm. B ii. Effect of IGF-1 and signaling 
pathway inhibitors on intercellular spaces: Photomicrographs of lectin-stained cultures 
confirm that IGF-1 abrogates intercellular spaces caused by OGD. All experimental 
groups are compared to the normoxia group. Concurrent treatment with IGF-
1 + LY294002 treated cultures shows greater gaps between cells compared to IGF-1 
group, while concurrent treatment with Rapamycin is no different from IGF-1 alone. 
Each data point is the average of 3 technical replicates, and shown here is the average 





Figure 3-4: Effect of post-stroke IGF-1 treatment on neurological function 1 day 
after MCAo 
Histogram depicts mean neurological score of vehicle (artificial CSF; aCSF), IGF-1 and 
IGF-1 + JB-1 treated groups. Neurological function was significantly better in IGF-1-
treated animals as compared to vehicle control and IGF-1 + JB-1 treated groups. All 
graphs represent mean ± S.E.M., n = 5–7 in each group, * p < 0.05. 
3.4.4. Effect of post-stroke IGF-1 treatment on vinculin staining 
Brain sections from animals subject to MCAo were probed for vinculin 
immunohistochemistry. Striatal and overlying cortical regions were analyzed for density 
of vinculin labeling. Representative sections of each group at 1 day post stroke are 
shown in Figure 3-5A. Punctate vinculin label was seen in the cortex and striatum of all 
experimental groups 24 h after ischemia-reperfusion (Figure 3-5A), however, vinculin 
staining density was significantly higher in the IGF-1-treated group as compared to the 
vehicle-treated controls or to groups that received concurrent IGF-1 + JB-1 (F(2,13): 
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5.021; p = 0.028) (interaction effect). At 5-day post-stroke, there was no statistical 
difference in vinculin staining density between treatment groups (Figure 3-5B).  
 
Figure 3-5: Effect of post-stroke IGF-1 treatment on vinculin expression (A) 1d 
post stroke 
 
Effect of post-stroke IGF-1 treatment on vinculin expression (A) 1d post stroke: 
Photomicrographs of vinculin immunostained representative sections from the ischemic 
cortex and striatum of control (i,ii), IGF-1 treated (iii,iv) and IGF-1 + JB-1 treated (v,vi) 
animals. Histograms depict mean and SEM of the density of vinculin staining in each 
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group in the ischemic and non-ischemic hemisphere. (B) 5d after stroke: 
Photomicrographs of vinculin immunostained representative sections from the ischemic 
cortex and striatum of control (i,ii), IGF-1 treated (iii,iv) and IGF-1 + JB-1 treated (v,vi) 
animals. Histograms depict mean and SEM of the density of vinculin staining in each 
group in the ischemic and non-ischemic hemisphere. N = 4–6 in each group. *: p < 0.05. 
Bar: 100 um. 
 




3.4.5. Effect of post-stroke IGF-1 treatment on microvessel morphology 
Sections from control, IGF-1 and IGF-1 + JB-1 treated groups subject to MCAo 
were stained for lectin histochemistry. Representative sections of each group at 1 day 
post-stroke is shown in Figure 3-6A. A minimum of 50 vessels were analyzed per animal 
and grouped as small (1–5 μm) medium (6–10 μm) or large (11+ μm) diameter vessels. 
In the ischemic hemisphere, IGF-1-treated animals had a significantly greater proportion 
of large diameter vessels as compared to vehicle-treated controls or JB-1 treated animals 
(F(2,11) = 21.707; p < 0.001) and the lowest proportion of small diameter vessels 
(F(2,11) = 9.696; p = 0.004), indicating that IGF-1 treatment skews the distribution 
towards larger-diameter microvessels. A similar pattern was also seen in the non-
ischemic hemisphere, where IGF-1 treated animals displayed the highest proportion of 
large diameter vessels (F(2,12) = 6.639; p < 0.011), and the lowest proportion of small 
diameter vessels (1F(2,12) = 8.752; p = 0.005) as compared to vehicle treated controls 
and JB-1 treated animals. 
At 1 day post stroke, microvessel length was partly influenced by IGF-1 
treatment. There was a significant decrease in the proportion of short length vessels 
(F(2,11) = 4.169; p < 0.042), and a trend towards longer length vessels (F(2,12) = 3.01; 
p < 0.087) in IGF-1 treated animals as compared to vehicle treated controls or JB-1 
treated animals (Figure 3-6A). On the non-ischemic hemisphere, there were no 
differences in vessel length between IGF-1 and vehicle treated controls. 
At 5 days post stroke (Figure 3-6B), all groups had a similar proportion (19%–
20%) of large diameter vessels, while IGF-1 treated animals had more small diameter 
 82 
 
vessels and fewer medium diameter vessels as compared to vehicle treated controls or 
JB-1 treated animals. No treatment effects were noted for the non-ischemic hemisphere 
at 5d post stroke, although most microvessels fell in the medium and large diameter 
category unlike the ischemic side where most vessels fell in the medium and small 
diameter category, indicating an overall shift in vessel diameter due to ischemia. 
There were no treatment effects on microvessel length at 5d after stroke, in either 
the ischemic or non-ischemic hemisphere (Figure 3-6B). Moreover, both sides showed 
similar distributions in small, medium and large length vessels. Overall, IGF-1 exerted 





Figure 3-6: Effect of post-stroke IGF-1 treatment on microvessel morphology.  
(A) 1d post stroke: Photomicrographs of lectin-sectioned microvessels from the ischemic 
hemisphere of control (i), IGF-1 treated (ii) and IGF-1 + JB-1 treated (iii) animals. 
Histograms depict the mean distribution of microvessel diameter (top) and microvessel 
length (bottom) from the ischemic and non-ischemic hemisphere. IGF-1 treated animals 
showed greater number of vessels in the largest bin (11+) compared to vehicle control or 
IGF + JB-1 treated groups in both ischemic and non-ischemic sides, and fewer short 
length vessels on the ischemic hemisphere. * p < 0.05, main effect of IGF1 treatment. 
(B) 5d post stroke: Photomicrographs of lectin-stained microvessels from the ischemic 
 84 
 
hemisphere of control (i), IGF-1 treated (ii) and IGF-1 + JB-1 treated (iii) animals. 
Histograms depict the mean distribution of microvessel diameter (top) and microvessel 
length (bottom) from the ischemic and non-ischemic hemisphere. IGF-1-treated animals 
showed greater number of small diameter vessels as compared to other two groups in the 
ischemic hemisphere. N = 4–6 in each group. * p < 0.05, Bar: 100 um. 
Figure 3-6 Continued 
3.5. Discussion 
Our previous work showed that IGF-1 treatment to endothelial cell cultures 
protects the barrier properties of these cells under OGD conditions. We also reported 
that IGF-1 does not prevent cell death during OGD conditions, which seems paradoxical 
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in light of IGF-1's effects on barrier function. The current studies provide an answer to 
this paradox, by showing that while OGD conditions cause endothelial cells shrinkage 
(and therefore prominent intercellular spaces), IGF-1 treatment preserves the flattened 
morphology and anchorage of surviving cells (fewer intercellular spaces), thus 
potentially maintaining a more effective barrier. In view of the short duration of OGD 
(6 h), it is unlikely that the reduced intercellular space is due to cell proliferation, and 
likely represents IGF-1 action on the actin cytoskeleton of surviving cells. In vivo, 
microvessel diameter, a surrogate measure of cell contraction (Shen et al., 2009) showed 
that IGF-1 treated animals had larger microvessel diameter in the ischemic region at 24 h 
after stroke and greater density of vinculin staining, further supporting the idea that IGF-
1 stabilizes the endothelium. Together with our previous in vivo studies showing that 
IGF-1 treatment to middle-aged female rats decreases BBB permeability (Bake et al., 
2014) and infiltration of CD4+ cells into the ischemic brain (Bake et al., 2016), the 
current studies show that IGF-1 is a vasculoprotective factor in stroke. 
IGF-1 is considered neuroprotective because it reduces ischemic injury in many 
species (Gluckman et al., 1992; Lee et al., 1992; Johnston et al., 1996; Guan et al., 2001) 
and promotes neuronal survival, neuronal myelination and angiogenesis (Wang et al., 
2000; Smith, 2003). However, vascular pathology is among the earliest events in 
ischemic stroke. During the acute phase after reperfusion, accumulation of toxic oxygen 
radicals impair endothelial function leading to a leaky blood brain barrier. In the hours 
following stroke (sub-acute phase), barrier permeability is increased due to the 
generation of inflammatory cytokines, endothelial adhesion molecules and proteinases 
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such as MMPs that cause pathologic remodeling of the endothelium and the basement 
membrane. The chronic phase of stroke (days/weeks) involves regulation of apoptotic 
genes which leads to cell death as well as angiogenic factors that lead to repair. A recent 
study (Shi et al., 2016) showed that blood brain barrier leakiness seen in the earliest 
phase of ischemia (30 min) is independent of matrix cleavage and MMP production. 
During this time, BBB undergoes subtle changes including the rapid reorganization of 
the actin cytoskeleton in endothelial cells, which alters their morphology and permits 
fluid and small molecules to enter the brain, and these events precede neuronal damage. 
Accordingly, MMP-9 gene deletion failed to ameliorate the early leakiness of the BBB 
to small-sized dextrans, while overexpression of the actin depolymerization factor 
reduced leakiness to the small sized dextrans (Shi et al., 2016). This early ‘hyper-
permeability’ of the BBB facilitates diapedesis of peripheral immune cells and 
extravasation of plasma proteins that are toxic to neurons. Our studies suggest that IGF-1 
may rescue infarct volume using a similar vasculoprotective strategy. Thus, IGF-1 
treatment after MCAo reduces infarct volume when measured at 24 h, which is preceded 
by reduced BBB hyper-permeability in the early hours after stroke (4 h) (Bake et al., 
2014). The current studies build on this foundation to show that IGF-1 treatment acts 
directly on endothelial cells to preserve the actin cytoskeleton and its anchorage. 
The in vitro model used in these studies show that the effect of IGF-1 on 
endothelial cell geometry is mediated by the PI3K pathway. Oxygen glucose deprivation 
(OGD) is commonly used to model cerebral ischemia in vitro (Doukas et al., 1994; 
Stanimirovic et al., 1997; Guo et al., 2012; Bake et al., 2016), and produces many of the 
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same events seen in in vivo ischemic models, including activation of cell death pathways 
(Liao et al., 2016), generation of reactive oxygen species, reduced ATP production (Imai 
et al., 2017), and dysregulates tight junction protein expression and barrier function (Shi 
et al., 2016). IGF-1 is known to regulate the PI3K/Akt signaling pathway in several cell 
types. In mouse fibroblasts, for example, IGF-1 reduces OGD-induced cell death which 
is reversed by the PI3K inhibitor LY294002 (Liu et al., 2017). However, inhibition of 
mTOR via rapamycin did not abrogate the effect of IGF-1 on intercellular spaces. This 
finding is surprising since recent studies show that, in addition to its role in cell survival, 
autophagy, nutrient/energy sensing, mTOR is also implicated in cell adhesion (Chen et 
al., 2015). Alternately, this process may be mediated by mTOR2, which is rapamycin 
insensitive (Jacinto et al., 2004). 
Changes in endothelial cell geometry is commonly seen after ischemia and 
ischemia-induced generation of free radicals and inflammatory cytokines (Gulino-
Debrac, 2013; Stamatovic et al., 2016). Formation of thick stress fibers results in cell 
contractions, loss of anchorage to the matrix, and loss of tight junctions. OGD increases 
stress fiber formation thus changing cell geometry to a narrow, elongated form and 
reduces anchorage to the matrix (van der Heijden et al., 2008; Gao et al., 2012; Alluri et 
al., 2014). Disorganized actin cytoskeleton, such as in the dystrophin KO mouse, leads 
to increased vascular permeability (Nico et al., 2003), indicating the importance of actin 
assembly in the maintenance of the endothelial barrier. IGF-1 may alter cytoskeletal 
dynamics through regulation of cell adhesion via extracellular matrix proteins such as 
collagen and integrins(Valastyan and Weinberg, 2011). This process may occur through 
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IGF-1 regulation of small non-coding RNA (miRNA) that act as translational repressors. 
Mir29 has been shown to increase collagen deposition and to improve outcomes in a 
renal injury model (Liu et al., 2010), and reduce fibrotic scars in a rat model of 
myocardial infarction (van Rooij et al., 2008). In silico analysis of vinculin shows 
consensus sites for mir29 and mir33, both of which are regulated by IGF-1 in vivo (Bake 
et al., 2016). However, further studies are warranted to examine the cytoskelelal 
regulatory role of these miRNAs in coordinating endothelial actin re-organization and 
cell-matrix adhesion under ischemia. 
The present study also indicates that IGF-1 may exert different effects in the 
early and late acute stages of ischemia. IGF-1 has been shown to affect more immediate 
processes such as glucose metabolism in astrocytes (Hernandez-Garzon et al., 2016) and 
activation of PI-3 K/Akt signaling in microglia (Streit, 2002) and cerebellar neurons 
(Dudek et al., 1997), as well as long-term changes such as proliferation (Torres-Aleman 
et al., 1998) and neurogenesis in the hypothalamus, olfactory bulb and hippocampus 
(Pixley et al., 1998; Perez-Martin et al., 2010; Pardo et al., 2016). Some of these 
processes may be linked such that early effects on actin cytoskeleton and substrate 
adhesion may have durable effects on other aspects of stroke recovery such as cell 
survival, while others may be independent processes. This may be specifically relevant 
in the case of microvessel morphology. Microvessel density and diameter are reduced 
during occlusion of the parent vessel, and then recover gradually at reperfusion and in 
the days following the stroke (Dziennis et al., 2015). Thus, in the control group, the 
proportion of microvessels in the large bin increases from day 1 after stroke to day 5. In 
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the IGF-1 group, the proportion of microvessels in the same large bin stays relatively 
stable between day 1 and day 5. Thus, it appears that IGF-1 prevents microvessel 
shrinkage during the crucial early period of ischemia, possibly improving 
microcirculation in the ischemic hemisphere, and subsequently decreasing blood brain 
barrier permeability and inflammation (shown in our previous studies (Bake et. al., 2014; 
Bake et. al., 2016). 
In conclusion, the data from the present study underscores the importance of the 
microvasculature as an important early target for stroke therapies in older females, and 
IGF-1 as a good candidate for stroke therapy. However, defining the effective dose and 
timing of IGF-1 will be critical for translational applications, since the majority of stroke 
patients may not arrive at a medical facility prior to 2 h. While IGF-1 improves stroke 
recovery, its effectiveness diminishes when the treatment is delayed. In a study 
comparing normotensive and hypertensive male rats, subcutaneous IGF-1 significantly 
decreased infarct volume when given 30 mins after ischemia, but not at 2 h or 4 h later 
(De Geyter et al., 2013). Similarly, intranasal IGF-1 was more effective in reducing 
infarct volumes when given at 2 h post-stroke (54%), as compared to 4 h after stroke 
(39%), however behavioral improvement was only seen with early (2 h) treatment (Liu 
et al., 2004), similar to data from our studies. The evidence presented here shows that 





Alluri, H., Stagg, H.W., Wilson, R.L., Clayton, R.P., Sawant, D.A., Koneru, M., 
Beeram, M.R., Davis, M.L., Tharakan, B., 2014. Reactive oxygen species-caspase-3 
relationship in mediating blood-brain barrier endothelial cell hyperpermeability 
following oxygen-glucose deprivation and reoxygenation. Microcirculation 21, 187–
195. 
 
Bake, S., Selvamani, A., Cherry, J., Sohrabji, F., 2014. Blood brain barrier and 
neuroinflammation are critical targets of IGF-1-mediated neuroprotection in stroke for 
middle-aged female rats. PLoS One 9, e91427. 
 
Bake, S., Okoreeh, A.K., Alaniz, R.C., Sohrabji, F., 2016. Insulin-like growth factor 
(IGF)-I modulates endothelial blood-brain barrier function in ischemic middle-aged 
female rats. Endocrinology 157, 61–69. 
 
Baldo, C., Lopes, D.S., Faquim-Mauro, E.L., Jacysyn, J.F., Niland, S., Eble, J.A., Clissa, 
P.B., Moura-Da-Silva, A.M., 2015. Jararhagin disruption of endothelial cell anchorage is 
enhanced in collagen enriched matrices. Toxicon 108, 240–248. 
 
Borlongan, C.V., Glover, L.E., Sanberg, P.R., Hess, D.C., 2012. Permeating the blood 
brain barrier and abrogating the inflammation in stroke: implications for stroke therapy. 
Curr. Pharm. Des. 18, 3670–3676. 
 91 
 
Chen, L., Xu, B., Liu, L., Liu, C., Luo, Y., Chen, X., Barzegar, M., Chung, J., Huang, S., 
2015. Both mTORC1 and mTORC2 are involved in the regulation of cell adhesion. 
Oncotarget 6, 7136–7150. 
 
De Geyter, D., Stoop, W., Sarre, S., De Keyser, J., Kooijman, R., 2013. Neuroprotective 
efficacy of subcutaneous insulin-like growth factor-I administration in normotensive and 
hypertensive rats with an ischemic stroke. Neuroscience 250, 253–262. 
 
Dimitrijevic, O.B., Stamatovic, S.M., Keep, R.F., Andjelkovic, A.V., 2007. Absence of 
the chemokine receptor CCR2 protects against cerebral ischemia/reperfusion injury in 
mice. Stroke 38, 1345–1353. 
 
Dinapoli, V.A., Huber, J.D., Houser, K., Li, X., Rosen, C.L., 2008. Early disruptions of 
the blood-brain barrier may contribute to exacerbated neuronal damage and prolonged 
functional recovery following stroke in aged rats. Neurobiol. Aging 29, 753–764. 
 
Doukas, J., Cutler, A.H., Boswell, C.A., Joris, I., Maino, G., 1994. Reversible 
endothelial cell relaxation induced by oxygen and glucose deprivation. A model of 




Dudek, H., Datta, S.R., Franke, T.F., Birnbaum, M.J., Yao, R., Cooper, G.M., Segal, 
R.A., Kaplan, D.R., Greenberg, M.E., 1997. Regulation of neuronal survival by the 
serinethreonine protein kinase Akt. Science 275, 661–665. 
 
Dziennis, S., Qin, J., Shi, L., Wang, R.K., 2015. Macro-to-micro cortical vascular 
imaging underlies regional differences in ischemic brain. Sci. Rep. 5, 10051. 
 
Gao, C., Li, R., Liu, Y., Ma, L., Wang, S., 2012. Rho-kinase-dependent F-actin 
rearrangement is involved in the release of endothelial microparticles during IFNalpha- 
induced endothelial cell apoptosis. J. Trauma Acute Care Surg. 73, 1152–1160. 
 
Gidday, J.M., Gasche, Y.G., Copin, J.C., Shah, A.R., Perez, R.S., Shapiro, S.D., Chan, 
P.H., Park, T.S., 2005. Leukocyte-derived matrix metalloproteinase-9 mediates blood-
brain barrier breakdown and is proinflammatory after transient focal cerebral ischemia. 
Am. J. Physiol. Heart Circ. Physiol. 289, H558–H568. 
 
Gluckman, P., Klempt, N., Guan, J., Mallard, C., Sirimanne, E., Dragunow, M., Klempt, 
M., Singh, K., Williams, C., Nikolics, K., 1992. A role for IGF-1 in the rescue of CNS 





Guan, J., Miller, O.T., Waugh, K.M., McCarthy, D.C., Gluckman, P.D., 2001. Insulin-
like growth factor-1 improves somatosensory function and reduces the extent of cortical 
infarction and ongoing neuronal loss after hypoxia-ischemia in rats. Neuroscience 105, 
299–306. 
 
Gulino-Debrac, D., 2013. Mechanotransduction at the basis of endothelial barrier 
function. Tissue Barriers 1, e24180. 
 
Guo, J., Duckles, S.P., Weiss, J.H., Li, X., Krause, D.N., 2012. 17beta-Estradiol prevents 
cell death and mitochondrial dysfunction by an estrogen receptor-dependent mechanism 
in astrocytes after oxygen-glucose deprivation/reperfusion. Free Radic. Biol. Med. 52, 
2151–2160. 
 
Hernandez-Garzon, E., Fernandez, A.M., Perez-Alvarez, A., Genis, L., Bascunana, P., 
Fernandez De La Rosa, R., Delgado, M., Angel Pozo, M., Moreno, E., McCormick, P.J., 
Santi, A., Trueba-Saiz, A., Garcia-Caceres, C., Tschop, M.H., Araque, A., Martin, E.D., 
Torres Aleman, I., 2016. The insulin-like growth factor I receptor regulates glucose 
transport by astrocytes. Glia. 64, 1962–1971. 
 
Imai, T., Mishiro, K., Takagi, T., Isono, A., Nagasawa, H., Tsuruma, K., Shimazawa, 
M., Hara, H., 2017. Protective effect of bendavia (SS-31) against oxygen/glucose-
 94 
 
deprivation stress-induced mitochondrial damage in human brain microvascular 
endothelial cells. Curr. Neurovasc. Res. 14, 53–59. 
 
Jacinto, E., Loewith, R., Schmidt, A., Lin, S., Ruegg, M.A., Hall, A., Hall, M.N., 2004. 
Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin 
insensitive. Nat. Cell Biol. 6, 1122–1128. 
 
Johnston, B.M., Mallard, E.C., Williams, C.E., Gluckman, P.D., 1996. Insulin-like 
growth factor-1 is a potent neuronal rescue agent after hypoxic-ischemic injury in fetal 
lambs. J. Clin. Invest. 97, 300–308. 
 
Khatri, R., McKinney, A.M., Swenson, B., Janardhan, V., 2012. Blood-brain barrier, 
reperfusion injury, and hemorrhagic transformation in acute ischemic stroke. Neurology 
79, S52–S57. 
 
Kleinschnitz, C., Wiendl, H., 2013. Con: Regulatory T cells are protective in ischemic 
stroke. Stroke 44, e87–e88. 
 
Kreuger, J., Phillipson, M., 2016. Targeting vascular and leukocyte communication in 




Lee, W.H., Clemens, J.A., Bondy, C.A., 1992. Insulin-like growth factors in the 
response to cerebral ischemia. Mol. Cell. Neurosci. 3, 36–43. 
 
Liao, L.X., Zhao, M.B., Dong, X., Jiang, Y., Zeng, K.W., Tu, P.F., 2016. TDB protects 
vascular endothelial cells against oxygen-glucose deprivation/reperfusion-induced injury 
by targeting miR-34a to increase Bcl-2 expression. Sci. Rep. 6, 37959. 
 
Liu, X.F., Fawcett, J.R., Hanson, L.R., Frey 2nd, W.H., 2004. The window of 
opportunity for treatment of focal cerebral ischemic damage with noninvasive intranasal 
insulin like growth factor-I in rats. J. Stroke Cerebrovasc. Dis. 13, 16–23. 
 
Liu, F., Yuan, R., Benashski, S.E., McCullough, L.D., 2009. Changes in experimental 
stroke outcome across the life span. J. Cereb. Blood Flow Metab. 29, 792–802. 
 
Liu, Y., Taylor, N.E., Lu, L., Usa, K., Cowley Jr., A.W., Ferreri, N.R., Yeo, N.C., Liang, 
M., 2010. Renal medullary microRNAs in Dahl salt-sensitive rats: miR-29b regulates 
several collagens and related genes. Hypertension 55, 974–982. 
 
Liu, Q., Guan, J.Z., Sun, Y., Le, Z., Zhang, P., Yu, D., Liu, Y., 2017. Insulin-like growth 
factor 1 receptor-mediated cell survival in hypoxia depends on the promotion of 




Merali, S., Cameron, J.I., Barclay, R., Salbach, N.M., 2016. Characterising community 
exercise programmes delivered by fitness instructors for people with neurological 
conditions: a scoping review. Health Soc. Care Community 24, e101–e116. 
 
Montagne, A., Barnes, S.R., Sweeney, M.D., Halliday, M.R., Sagare, A.P., Zhao, Z., 
Toga, A.W., Jacobs, R.E., Liu, C.Y., Amezcua, L., Harrington, M.G., Chui, H.C., Law, 
M.,Zlokovic, B.V., 2015. Blood-brain barrier breakdown in the aging human 
hippocampus. Neuron 85, 296–302. 
 
Moskowitz, M.A., Lo, E.H., Iadecola, C., 2010. The science of stroke: mechanisms in 
search of treatments. Neuron 67, 181–198. 
 
Nico, B., Frigeri, A., Nicchia, G.P., Corsi, P., Ribatti, D., Quondamatteo, F., Herken, R., 
Girolamo, F., Marzullo, A., Svelto, M., Roncali, L., 2003. Severe alterations of 
endothelial and glial cells in the blood-brain barrier of dystrophic mdx mice. Glia 42, 
235–251. 
 
Okoreeh, A.K., Bake, S., Sohrabji, F., 2017. Astrocyte-specific insulin-like growth 





Pardo, J., Uriarte, M., Console, G.M., Reggiani, P.C., Outeiro, T.F., Morel, G.R., Goya, 
R.G., 2016. Insulin-like growth factor-I gene therapy increases hippocampal 
neurogenesis, astrocyte branching and improves spatial memory in female aging rats. 
Eur. J. Neurosci. 44, 2120–2128. 
 
Paxinos, G., Watson, C., 1986. The Rat Brain in Stereotaxic Coordinates. Academic 
Press Inc, New York.  
 
Perez-Martin, M., Cifuentes, M., Grondona, J.M., Lopez-Avalos, M.D., Gomez-Pinedo, 
U., Garcia-Verdugo, J.M., Fernandez-Llebrez, P., 2010. IGF-I stimulates neurogenesis in 
the hypothalamus of adult rats. Eur. J. Neurosci. 31, 1533–1548.  
 
Pixley, S.K., Dangoria, N.S., Odoms, K.K., Hastings, L., 1998. Effects of insulin-like 
growth factor 1 on olfactory neurogenesis in vivo and in vitro. Ann. N. Y. Acad. Sci. 855, 
244–247. 
 
Pulsinelli, W., 1992. Pathophysiology of acute ischaemic stroke. Lancet 339, 533–536. 
Selvamani, A., Sohrabji, F., 2010a. The neurotoxic effects of estrogen on ischemic 
stroke in older female rats is associated with age-dependent loss of insulin-like growth 




Selvamani, A., Sohrabji, F., 2010b. Reproductive age modulates the impact of focal 
ischemia on the forebrain as well as the effects of estrogen treatment in female rats. 
Neurobiol. Aging 31, 1618–1628. 
 
Shen, Q., Wu, M.H., Yuan, S.Y., 2009. Endothelial contractile cytoskeleton and 
microvascular permeability. Cell Health Cytoskeleton 2009, 43–50. 
 
Shi, Y., Zhang, L., Pu, H., Mao, L., Hu, X., Jiang, X., Xu, N., Stetler, R.A., Zhang, F., 
Liu, X., Leak, R.K., Keep, R.F., Ji, X., Chen, J., 2016. Rapid endothelial cytoskeletal 
reorganization enables early blood-brain barrier disruption and long-term ischaemic 
reperfusion brain injury. Nat. Commun. 7, 10523. 
 
Smith, P.F., 2003. Neuroprotection against hypoxia-ischemia by insulin-like growth 
factor-I (IGF-I). IDrugs 6, 1173–1177. 
 
Stamatovic, S.M., Johnson, A.M., Keep, R.F., Andjelkovic, A.V., 2016. Junctional 
proteins of the blood-brain barrier: New insights into function and dysfunction. Tissue 
Barriers 4, e1154641. 
 
Stanimirovic, D.B., Ball, R., Durkin, J.P., 1997. Stimulation of glutamate uptake and 




Streit, W.J., 2002. Microglia as neuroprotective, immunocompetent cells of the CNS. 
Glia 40, 133–139. 
 
Torres-Aleman, I., Villalba, M., Nieto-Bona, M.P., 1998. Insulin-like growth factor-I 
modulation of cerebellar cell populations is developmentally stage-dependent and 
mediated by specific intracellular pathways. Neuroscience 83, 321–334. 
 
Valastyan, S., Weinberg, R.A., 2011. Roles for microRNAs in the regulation of cell 
adhesion molecules. J. Cell Sci. 124, 999–1006. 
 
van der Heijden, M., Versteilen, A.M., Sipkema, P., van Nieuw Amerongen, G.P., 
Musters, R.J., Groeneveld, A.B., 2008. Rho-kinase-dependent F-actin rearrangement is 
involved in the inhibition of PI3-kinase/Akt during ischemia-reperfusion-induced 
endothelial cell apoptosis. Apoptosis 13, 404–412. 
 
van Rooij, E., Sutherland, L.B., Thatcher, J.E., Dimaio, J.M., Naseem, R.H., Marshall, 
W.S., Hill, J.A., Olson, E.N., 2008. Dysregulation of microRNAs after myocardial 





Wang, J.M., Hayashi, T., Zhang, W.R., Sakai, K., Shiro, Y., Abe, K., 2000. Reduction of 
ischemic brain injury by topical application of insulin-like growth factor-I after 
transient middle cerebral artery occlusion in rats. Brain Res. 859, 381–385. 
 
Wu, L., Walas, S., Leung, W., Sykes, D.B., Wu, J., Lo, E.H., Lok, J., 2015. 
Neuregulin1-beta decreases IL-1beta-induced neutrophil adhesion to human brain 
microvascular endothelial cells. Transl Stroke Res 6, 116–124. 
 
Yang, Y., Estrada, E.Y., Thompson, J.F., Liu, W., Rosenberg, G.A., 2007. Matrix 
metalloproteinase- mediated disruption of tight junction proteins in cerebral vessels is 
reversed by synthetic matrix metalloproteinase inhibitor in focal ischemia in rat. J. 
Cereb. Blood Flow Metab. 27, 697–709. 
 
Zhu, L., Han, B., Wang, L., Chang, Y., Ren, W., Gu, Y., Yan, M., Wu, C., Zhang, X.Y., 
He, J., 2016. The association between serum ferritin levels and post-stroke depression. J. 
Affect. Disord. 190, 98–102. 
 101 
 
4. THIRD STUDY: ASTROCYTE-SPECIFIC INSULIN-LIKE GROWTH FACTOR-1 
(IGF-1) GENE TRANSFER IN AGING FEMALE RATS IMPROVES STROKE 
OUTCOMES3 
 
4.1. Overview of the Third Study 
Middle aged female rats sustain larger stroke infarction and disability than 
younger female rats. This older group also shows age-related reduction of insulin like 
growth factor (IGF)-1 in serum and in astrocytes, a cell type necessary for post stroke 
recovery. To determine the impact of astrocytic IGF-1 for ischemic stroke, these studies 
tested the hypothesis that gene transfer of IGF-1 to astrocytes will improve stroke 
outcomes in middle aged female rats. Middle aged (10–12 month old), acyclic female 
rats were injected with recombinant adeno-associated virus serotype 5 (AAV5) packaged 
with the coding sequence of the human (h)IGF-1 gene downstream of an astrocyte-
specific promoter GFAP (AAV5-GFP-hIGF-1) into the striatum and cortex. The AAV5-
control consisted of an identical shuttle vector construct without the hIGF-1 gene 
(AAV5-GFAP-control). Six to eight weeks later, animals underwent transient (90 mins) 
middle cerebral artery occlusion via intraluminal suture. While infarct volume was not 
altered, AAV5-GFAP-hIGF-1 treatment significantly improved blood pressure and 
neurological score in the early acute phase of stroke (2 days) and sensory-motor 
                                                 
3 Reprinted with permission from Okoreeh AK, Bake S, Sohrabji F. Astrocyte-specific 
insulin-like growth factor-1 gene transfer in aging female rats improves stroke outcomes. 




performance at both the early and late (5 days) acute phase of stroke. AAV5-GFAP-
hIGF-1 treatment also reduced circulating serum levels of GFAP, a biomarker for blood 
brain barrier permeability. Flow cytometry analysis of immune cells in the brain at 24h 
post stroke showed that AAV5-GFAP-hIGF-1 altered the type of immune cells 
trafficked to the ischemic hemisphere, promoting an anti-inflammatory profile. 
Collectively, these studies show that targeted enhancement of IGF-1 in astrocytes of 
middle-aged females improves stroke-induced behavioral impairment and 
neuroinflammation. 
4.2. Introduction 
Ischemic stroke is the 5th leading cause of mortality, and the major cause of long 
term disability, especially among the elderly (Mozaffarian et al. 2015). Loss of nutrients, 
due to occlusion of a cerebral vessel, initiates a sequence of damaging events within 
neurons including rapid failure of ATP-dependent processes (Rossi et al. 2007), 
increased release of glutamate and calcium (Bano et al. 2005), and a loss of cellular 
integrity (Lo et al. 2003). Transient ischemia, followed by reperfusion, also increases 
permeability of the blood brain barrier and increases brain trafficking of cytotoxic cells 
and proteins. Non-neuronal cells such as astrocytes and endothelial cells, that are critical 
constituents of the blood brain barrier, also play a critical role in ischemic injury and 
repair (Panickar and Norenberg 2005; Posada-Duque et al. 2014). 
Astrocytes are well positioned for neuroprotection during ischemia. They provide 
growth factors (Karki et al. 2014), clear glutamate (Olsen and Sontheimer 2008), 
preserve blood brain barrier function (Abbott et al. 2006) (Cekanaviciute and 
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Buckwalter 2016), interact with the immune system (Xie and Yang 2015), combat 
oxidative stress (Xu et al. 2010) and produce functional extracellular mitochondria to 
support neuronal viability (Hayakawa et al. 2016). Astrocytes are less vulnerable to 
ischemic injury than neurons (Dienel and Hertz 2005)and have a greater capacity for 
self-preservation (Allaman et al. 2011), indicating that these cells may play a crucial role 
in post-stroke recovery. 
The ability of astrocyte’s to promote neuroprotection deteriorates with age, when 
the CNS is more prone to disease pathology particularly stroke (reviewed in Chisholm et 
al., 2015). Proliferation of reactive astrocytes after injury is greater (Topp et al. 1989) 
and persists longer in the aged brain (Manwani et al. 2011) and results in accelerated 
glial scar formation in this group (Badan et al. 2003). Aged reactive astrocytes exhibited 
an upregulation of genes associated with inflammation and scar formation as compared 
to adult astrocytes (Buga et al. 2008). Moreover, aging also affects astrocytic functions 
critical for stroke recovery such reduced glutamate uptake capacity in aging male rats 
(Latour et al. 2013) and in middle aged female rats (Lewis et al. 2012). Similarly, while 
astrocytes normally release a variety of trophic factors that promote neuronal survival 
and curb CNS degeneration (Ridet et al. 1997) including IGF-1 and VEGF (Chisholm 
and Sohrabji 2016), these secretions decrease with age (Bhat et al. 2012; Lewis et al. 
2012). The loss of IGF-1 observed in aging astrocytes may result in more severe stroke 
outcomes observed in middle aged female rats. 
IGF-1 plays an important role in development, cell differentiation, neuronal 
plasticity, and cell survival of the nervous system (Bondy and Cheng 2004). IGF-1 also 
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reduces cell death in a variety of experimental neurologic disease models, such 
Parkinson’s (Ayadi et al. 2016) traumatic brain injury (Madathil et al. 2013), and spinal 
cord injury (Utada et al. 2015). With age, plasma levels of IGF-1 decrease in many 
species and in female rats, this decrease is seen as early as middle age, when stroke 
induced infarction is more severe as compared to young females (Selvamani and 
Sohrabji, 2010). Intracerebroventricular (ICV) treatment with IGF-1 post-stroke has 
been reported to decrease infarct volumes in this group (Bake et al., 2014), suggesting 
that the loss of IGF-1 with age may underlie the more severe stroke outcomes seen in 
middle-aged females. 
In view of the crucial role that astrocytes play in brain injury along with the age-
related loss of IGF-1 in middle-aged females, we hypothesize that worse stroke 
outcomes in this age group is due to reduced availability of astrocytic IGF-1, and that 
increasing IGF-1 expression in aging astrocytes will improve post-stroke outcomes in 
this group. To test this hypothesis, middle-aged females were injected with recombinant 
human (h)IGF-1 placed downstream of the GFAP promoter and packaged in 
recombinant adeno-associated virus serotype 5 (AAV5) or with control construct. 
Following stroke, animals were tested for behavioral impairments, extent of infarction, 
and neuroinflammation. Our studies show that gene transfer of IGF-1 to astrocytes 
significantly improves stroke-induced behavioral impairment, without reducing infarct 




4.3. Materials and Methods 
4.3.1. Animals 
Female Sprague Dawley (SD) rats were purchased as retired breeders (10 – 12 
months; weight range 325 – 350 g) from Envigo Laboratories. This group met our 
previously established criteria for reproductive senescence: briefly, at least five 
successful pregnancies and current acyclicity as defined by vaginal cytology assessed via 
daily vaginal smears (Jezierski and Sohrabji 2001). All animals were housed in an 
AAALAC–approved facility, maintained on a constant photoperiod (12-hour light/dark 
cycles), and fed ad libitum with laboratory chow (Harlan Teklad 8604) and water. All 
animal procedures were performed in accordance with the National Institutes of Health 
guidelines for the humane care of laboratory animals and were approved by the 
Institutional Animal Care Committee and the Institutional Biosafety Committee. A total 
of 112 animals were used in this study. 
4.3.2. Adenovirus constructs 
Recombinant adeno associated virus serotype 5 (AAV5) was packaged 
(Signagen, MD) with the ORF of the human (h)IGF-1 gene downstream of the astrocyte-
specific promotor, GFAP (AAV5-GFAP-hIGF-1; see Figure 4-1). The construct also 
contained the mCherry reporter gene under the CMV minimal promoter to visually 
detect transfected cells. The control construct consisted of an identical shuttle vector 





Figure 4-1: AAV5 constructs. 
Schematic representations of the AAV serotype 5 viral constructs for AAV5-GFAP-
hIGF-1 (1A) and AAV5-GFAP-control (1B). (C.) AAV5 virus was injected into the 
cortex and the striatum on the same hemisphere. 
 
4.3.3. Surgical Procedures 
 AAV5 Injections 
Animals were anesthetized (ketamine: 87 mg/kg; xylazine: 13 mg/kg) and placed 
in a stereotaxic instrument (David Kopf Instruments). Two small holes were drilled into 
the skull at the following coordinates relative to bregma. For striatum: +0.9 mm anterior 
posterior, +3.6 mm medial lateral, and a depth of 6.5 mm relative to the dura. For cortex: 
+0.9 mm anterior posterior, +5.5 mm medial lateral, and a depth of 6.0 mm relative to 
the dura. In each case, a needle, attached to a Hamilton syringe was lowered to the 
required depth and AAV5 was delivered slowly to the parenchyma at the rate of 0.02 
μL/30 seconds for a total of 3.5 μL. All animals received one injection each into both the 
right striatum and right cortex of either the AAV5-GFAP-hIGF-1 construct or the 
AAV5-GFAP-control construct (Figure 1C). Two concentrations of AAV5 were used: 
2.5 ×1011 viral particles (VP)/mL (low dose) and 2.5 × 1012 (VP)/mL (high dose). 
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Animals were allowed to recover for 6–8 weeks after injections to allow full integration 
of the viral particles. 
 Middle cerebral artery occlusion (MCAo) 
Animals were subjected to middle cerebral artery occlusion (MCAo) via 
intraluminal suture using our previous procedures (Bake et al. 2016; Bake et al. 2014). 
Briefly, rats were anesthetized with isoflurane and maintained at 37°C on heating pads in 
dorsal recumbency. The neck region was shaved and disinfected and a ventral midline 
incision was made on the skin. Superficial fascia on the right side of the neck was 
dissected and the underlying muscles were blunt dissected to expose the right common 
carotid (CCA), external (ECA), and internal carotid (ICA) arteries. The ECA was 
separated from the vagus nerve and tied off distally with silk sutures after cauterizing the 
small branches. Microsurgical clamps were placed on the CCA and ICA. A loose tie was 
placed on the ECA, and the free stump of ECA was aligned with the ICA. Twenty-two 
mm of suture of the appropriate size with a silicon-coated round tip (Doccol Corp., CA) 
was inserted into ICA lumen through a small nick on the ECA between the two ties. The 
suture was advanced along the ICA until it reached the origin of the MCA (~20 mm of 
suture) and secured in position with nylon ties. The intraluminal suture was maintained 
for 90 min and then withdrawn. Tissue perfusion rate was monitored using Laser-
Doppler Flowmetry (Moor Instruments, UK) and the perfusion index was calculated for 
both ischemic and reperfusion time points. MCAo resulted in an 80% reduction of blood 
flow compared to the pre-occlusion rate and re-perfusion restored the perfusion index 
back to pre-occlusion levels. In a subset of animals, a permanent (p)MCAo was 
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performed, where the suture was maintained in place for the duration of the experiment. 
All animals were carefully monitored after surgery and terminated 2 days (early acute 
phase) or 5 days (late acute phase) after ischemia. 
4.3.4. Confirmation of AAV5 localization 
A subset of AAV5-GFAP-control and AAV5-GFAP-hIGF-1 injected animals 
were terminated 2 days after MCAo and processed for histological analyses to determine 
uptake of the AAV5 construct. Animals were perfused transcardially with dPBS 
(Thermo Fisher, MA) followed by 4% paraformaldehyde. The brains were removed 
from the cranial vault and post fixed in 4% paraformaldehyde overnight at 4°C. Brains 
were transferred to 15% sucrose overnight at 4°C and subsequently embedded in 
Richard-Allan Scientific Neg 50TM (ThermoFisher, MA) and then sectioned (30 microns) 
using a cryostat (Microm HM 550, ThermoFisher, MA). 
Sections were collected on superfrost slides (Thermo Scientific, MA), air dried, 
and fixed with 4% paraformaldehyde for 30 mins and blocked in blocking buffer (2% 
normal goat serum or rabbit serum and 0.2% triton X-100 in dPBS) for 1 hour at room 
temperature. Sections were then incubated with primary antibodies for hIGF-1 (Sigma, 
1:80 dilution) or GFAP (Sigma, CA, 1:80 dilution), (overnight ~16 hours) followed by a 
1 hour incubation with fluorescent-labeled secondary antibodies (Oregon green 488 
donkey anti-goat, 1:500 dilution and Oregon green 488 goat anti-rabbit, 1:500 dilution, 
respectively). Fluorescent labeling was visualized on the Olympus FSX100 Bio Imaging 




4.3.5. Infarct Analysis 
Infarct volume was measured using our previous published procedures 
(Selvamani and Sohrabji 2010). Two or 5 days after MCAo rats were deeply 
anesthetized and decapitated, and the brain was rapidly removed. Coronal slices (2 mm 
thick) between −2.00 mm and +4.00 mm from bregma were sectioned in an adult rat 
brain slicer matrix (Roboz Surgicals, Gaithersburg, MD) and incubated in a 2% 
Triphenyl tetrazolium chloride (TTC) solution at 37°C for 20 mins. Stained slices were 
photographed using an Olympus E950 digital camera attached to a dissecting 
microscope Infarct volume was determined from digitized images using the Quantity 
One software package (Bio-Rad, CA). Typically, 3 such slices were used for analysis. 
The area of the cortical and striatal infarct was measured separately in all slices, and the 
area of the entire contralateral hemisphere was also measured. The volume of the infarct 
was normalized to the volume of the contralateral (non-occluded) hemisphere. To ensure 
reliable and consistent detection of the infarct zone, images were digitally converted to 
black and white and magnified. Images were coded and the sections were analyzed by an 
investigator blind to the code (AO). 
4.3.6. Behavioral analysis 
Animals were evaluated for sensorimotor performance pre- and post- stroke 
using the vibrissae evoked forelimb placing task (Woodlee et al. 2005) as described in 
(Selvamani and Sohrabji 2010). Animals were subject to same-side placing trials and 
cross-midline placing trials elicited by stimulating the ipsi- and contra-lesional vibrissae. 
Same-side placing test: The animal was gently held such that all four limbs were free to 
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move. The animal’s ipsi-lesional vibrissae were brushed against the edge of a table to 
elicit a forelimb placing response, which typically consisted of the forelimb ipsi-lateral 
to the stimulated vibrissae. Ten trials were performed before the same was repeated for 
the contra-lesional vibrissae. 
4.3.7. Cross-midline placing test  
The animal was held gently by the upper body such that the ipsi-lesional 
vibrissae lie perpendicularly to the tabletop and the forelimb on that side is gently 
restrained as the vibrissae was brushed on the top of the table to evoke a response from 
the contralateral limb and vice versa. Between each trial, the animal was allowed to rest 
all four limbs briefly on the tabletop to help relax its muscles. Trials in which the animal 
seemed to struggle or make premature forelimb movements were not counted. 
The vibrissae-elicited forelimb placing test was carried out after AAV5 injection, but 
before and after MCAo surgeries. An unscored pretest was performed 3 days before 
MCAo to help acclimatize the animal to the testing procedure. The scored testing 
schedule was as follows: 2 days prior to the MCAo, 48h (2d after MCAo) and 5d after 
MCAo. Each testing and pretesting session consisted of 40 trials per animal, 10 trials 
each for the same-side placing (left and right) and 10 trials each for left and right cross-
midline placing. Each trial is rapid and the entire procedure on a single day is 
approximately 5 min/animal. 
Scoring was based on a 4-point scale. A vibrissae-elicited response of the 
forelimb that included a brisk forward and upward movement that ended in the paw pads 
making a flat, full contact with the tabletop was scored as 3. If there was a slow or 
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sluggish movement of the limb forward and upward, resulting in just the toes or claws 
contacting the tabletop, the trial was given a score of 2. When there was a limb 
movement forward but not upward and the paw made no contact with the tabletop, the 
trial was scored 1. If the limb did not move in response to stimulation, the trial was given 
a score 0. Trials scored as a 2 or 3 were counted as a successful placement and the once 
scored 1 or 0 were considered unsuccessful. 
4.3.8. Neurological Score 
A neurological score was obtained based on the following functional tests that 
were performed 2 days after MCAo. Described below are five tests performed in 
succession for each animal. For each test, a higher score indicates a more severe deficit. 
 Motility Test  
Animals were placed on an open surface and their movement was monitored. 
Animals that walked normally received a score of 0. Animal with any difficulties were 
given a 1. Deficits includes immobility, inability to walk straight, circling and falling 
down (Normal = 0, maximum = 1). 
 Grasping  
Animals were suspended by its forelimbs on a small beam. Grasping ability and 
forelimb strength were assessed. Animals that grasped the beam with both paws were 
given a 0. Animals that grasped only with the ipsi-lesional paw were given a 1. Animals 





 Righting Reflex  
To test the righting reflex, rats were placed on their backs. If the animal took less 
than 3 seconds to right itself, the animal received a score of 0. An animal that took 
longer than 3 seconds or was not able to perform the task was given a score of 1. 
(Normal = 0, maximum = 1) 
 Forepaw Disability  
Animals were placed a cylinder and observed. Animals that were able to rear and 
make contact with the wall of the cylinder with both paws were scored as 0. Animals 
that were only able to consistently place the ipsi-lesional paw were scored 1. Animals 
didn’t place either paw in 2 mins, were scored as 2. (Normal = 0, maximum = 2) 
 Circling  
Animals with no circling behavior were given a 0. Animals with an inability to 
walk straight and a flexion of the forelimb towards the paretic side after suspension by 
the tail were given a score of 1. Animals with constant circling to the paretic side were 
given a score of 2. Animals with constant circling to the paretic side which a slight 
tendency to fall were given a score of 3. Animals that were barreling were given a score 
of 4. Animals that were comatose were given a score of 5. (Normal = 0, maximum = 5) 
4.3.9. Physiological measurements 
 Body weight  
Animals were weighed before and after MCAo (2 days) and body weight 




 Systolic Blood Pressure  
Blood pressure was determined by Tail Cuff Blood Pressure Systems (IITC Life 
Science Inc, CA). Three days prior to baseline testing rats were placed in the apparatus 
to help acclimatize the animal to the testing environment. A pre-recording was 
performed 2 days prior to MCAo and a post-surgery recording was performed 2 days 
after surgery. Each testing and pretesting session consisted of 8 readings per animal, 
which were averaged. 
4.3.10. Quantitative RT-PCR 
 mRNA isolation  
Total RNA was extracted using the Qiagen miReasy kit (Qiagen, CA) from the 
ischemic and non-ischemic hemispheres as well as astrocytes obtained by magnetic 
purification from a different set of ischemic and non-ischemic hemispheres. For each 
sample, 15 μL was transferred to a new tube, and 700 μL QIAzol lysis reagent was 
added. Following a 5-min incubation at RT, 140 μL chloroform was added to each 
sample. Following a 2 min incubation at RT, samples were centrifuged at 12,000 × g for 
15 min at 4°C. The aqueous phase was then transferred to a fresh tube and mixed with 
ethanol (1.5 vol). The sample was then loaded on to an RNeasy Mini Spin Column and 
centrifuged for 30 seconds at RT, 13,000 × g. After sequential washes in RWT and RPE 
buffers, the columns were transferred to a fresh tube and RNA eluted with 50 μL of 
DNase/RNase-free water. Sample purity was assessed by Nanodrop technology and a 




 Real-time RT-PCR  
mRNA expression for specific genes in AAV5-GFAP-control and AAV5-GFAP-
hIGF-1 -treated animals was assessed using real-time qRT-PCR. 200 ng of purified total 
RNA was used to generate cDNA, using a Universal cDNA Synthesis Kit (Exiqon, 
Denmark) according to the manufacturer’s protocol. 1 μL of cDNA samples were used 
as a PCR reaction template in a 10 μl PCR reaction. PCR reactions were run in triplicate 
on an Applied Biosystems 7900HT real-time PCR instrument (Applied Biosystems, CA) 
using a SYBR green-based real-time PCR reaction kit (Exiqon, Denmark). 18s mRNA 
was used as a normalization control. Specificity of the amplification was evaluated by 
thermal stability analysis of the amplicon. Individual and reference gene primer sets 
(Integrated DNA Technologies, Coralville, IA) are listed in the Table 4-1. 
 
 
Gene Name Forward Primer Reverse Primer 
Human IGF-1 AGATGCACACCATGTCCTCC CATCCACGATGCCTGTCTGA 
Rat IGF-1 GCTGGTGGACGCTCTTCAGT TTCAGCGGAGCACAGTACAT 
 





Gene Name Forward Primer Reverse Primer 
GLAST AATGAAGCCATCATGAGATTGGT CCCTGCGATCAAGAAGAGGAT 
GFAP GGTGGAGAGGGACAATCTCA CCAGCTGCTCCTGGAGTTCT 
Iba1 CCATGAAGCCTGAGGAAATTTCA TTATATCCACCTCCAATTAGGGCA 
PECAM TTGTGACCAGTCTCCGAAGC TGGCTGTTGGTTTCCACACT 
18S ATGGCCGTTCTTAGTTGGTG CGCTGAGCCAGTCAGTGTAG 
Table 4-1 Continued 
 
4.3.11. Cell preparation 
Animals were anesthetized (xylazine and ketamine i.p.) and perfused 
intracardially with 100 mL of cold 1X PBS. Ischemic and non-ischemic hemispheres 
were collected and minced using a blade. Following a wash with X-VIVO 15 (Lonza, 
TX), a chemically-defined, serum free hematopoetic medium, tissues were first 
enzymatically dissociated using the Neural Dissociation Kit P (Miltenyi Biotech, CA) 
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and then transferred to a glass Dounce homogenizer and mechanically dissociated. The 
suspension was then filtered through a 30 μm strainer, and washed twice in X-VIVO 15. 
4.3.12. For astrocyte separation  
Cells were incubated with anti-GLAST antibody (1:5) for 10 min. GLAST was 
selected as a marker because it is an astrocyte-specific, membrane-associated protein and 
results in a virtually pure astrocyte population (Chisholm et al. 2015). Cells were then 
washed and spun at 300 × g for 10 min followed by incubation with biotin microbeads 
for 15 min. Cells were subsequently washed, spun (300 × g; 10 min), and resuspended in 
2 mL of buffer and passed through LS columns. The columns were washed with buffer 
(3× 3 mL), and the flow-through discarded. The LS column was then removed from the 
magnetic stand. Astrocytes were then eluted from the column and washed in cold dPBS. 
4.3.13. For flow cytometry of immune cells  
The cell pellet retrieved was resuspended in 6 ml of X-VIVO 15, and applied to 
an Opti-Prep gradient (Axis Shield, Olso, Norway). The gradient was composed of four 
1-mL layers of Opti-prep diluted in X-VIVO 15, arranged in the following order (from 
bottom to top): 35%, 25%, 20%, and 15%. The 10 mL tube containing the cell 
suspension and gradient was centrifuged at 1900 RPM for 15 min at 20°C with low 
acceleration and no brake. Following centrifugation, the top 7 mL of solution containing 
myelin and debris, was aspirated and discarded. The remaining 3 mL, containing 
inflammatory cells and glia, was washed twice in X-VIVO 15 and counted (Countess, 
Life Technologies). The single-cell suspension was then pipetted into three 96-well 
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plates and incubated with conjugated antibodies for the following markers: CD11b, Iba1, 
CD45, CD86, CD68, CD206, CD163, CD4, CD25, and FoxP3. 
For each animal, 2 technical replicates were prepared and phenotyped using a 
FACSAria flow cytometer (BD Biosciences, CA) and analyzed with FlowJo software 
(Tree Star Inc., OR). The following gating strategy was used to identify 
microglia/macrophages. First, dead cells and debris was removed from the analysis by 
gating on forward and side scatter. To control for cellular auto-fluorescence, unstained 
samples were prepared. Any cells determined to be positive were selected in a gate with 
>1% unstained cells. CD45+ cells were selected and further separated into discrete 
populations of high, medium, and low based on fluorescence intensity. For 
macrophages/microphages, after CD45+ positive only cells were selected, an initial gate 
was scaled to select discrete populations that were positive for both Iba1 and CD11b. For 
all further analysis, a quadrant system was created so that 99% of the unstained cells 
were in the third quadrant to determine phenotype and receptor expression. For Tregs, 
only CD45 high positive cells were used for analysis. An initial gate was scaled to select 
discrete population positive for CD4. For all further analysis, a quadrant system was 
created using CD25 and FoxP3 fluorescence so that 99% of the unstained cells were in 
the third quadrant to determine phenotype and receptor expression. 
4.3.14. ELISA Assays 
 Serum GFAP  
Concentrations of circulating glial fibrillary acidic protein (GFAP) in serum were 
determined by ELISA (R&D Systems), according to manufacturer’s instructions. 
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Briefly, standards, controls, and aliquots of serum samples were loaded into a 96-well 
plate precoated with antibodies specific for GFAP and incubated at room temperature for 
2 hours. With intervening washes, plates were sequentially incubated with 100 μL of 
conjugate for 2 hours, and 100 μL of substrate solution for 30 minutes. The color 
reaction was stopped by an equal volume of stop solution and read at 450 nm in a 
microplate reader (Bio-Tek, VT). Standard curves were established from optical 
densities of wells containing known dilutions of standard (1.56 – 100 ng/mL) using KC3 
software (Bio-Tek), and sample measurements were interpolated from standard curves. 




 Multiplex Cytokine Kit  
Tissue expression for a panel of cytokine/chemokine was measured in the 
ischemic and non-ischemic hemisphere and serum of rAAV5-GFAP-hIGF-1 and 
rAAV5-GFAP-control animals, using a multiplexed magnetic bead immunoassay 
(Milipore Corp., MA) following manufacturer’s instructions. Briefly, the filter plate was 
blocked with assay buffer for 10 min and decanted. Standards and samples was added 
into appropriate wells, followed by addition of premixed beads and incubated for 2 hour 
at room temperature on a plate shaker. Wells were washed 2 times, 25 μL of detection 
antibody was added, incubated for 1 hour incubation at RT and followed by 30 min 
incubation with addition of 25 μL of streptavidin-phycoerythrin per well. After 2 
washes, beads were resuspended in 150 μL of sheath fluid and a minimum of 50 beads 
per analyte was analysed in a Bio-Plex suspension array system (Bio-Rad Laboratories, 
CA). Cytokine/chemokine levels were normalized to total protein content. The following 
chemokines and cytokines were assessed: Granulocyte colony stimulating factor (G-
CSF), eotaxin, GM-CSF, interleukin (IL)-1α, leptin, macrophage inflammatory protein 
(MIP)-1a, MIP2, IL-4, IL1-b, IL-2, IL-6, EGF, IL-13, IL-10, IL-12 phosphorylated 70 
KDa (IL-12-p-70), Interferon (IFN)-γ, IL-5, IL-17A, IL-18, Chemokine C-motif Ligand 
(CCL2), Interferon gamma induced protein (IP)-10, Growth related 
oncogene/Keratinocyte derived chemokine (GRO/KC), VEGF, Fractalkine, 
Lipoploysacharide-induced CXC (LIX) chemokine, MIP-2, Tumor necrosis factor 




4.3.15. Statistical analyses 
Group size was determined using power analyses. Power analyses was computed 
based on effect sizes seen in previous data and pilot studies. In order to achieve power of 
0.8 (1-β) and Type 1 error rate α=0.05, the minimum sample size is 4. For these studies, 
most group sizes ranged from 5 to 8. The Kaplan Maier test was used for survival 
analysis. For behavioral tests, a paired t-test was used for each group, comparing the 
values obtained pre- and post-stroke. For all other tests, an unpaired t-test was 
performed. Group differences were considered significant at p<0.05 in each case. The 
statistical package SPSS (v. 21, IBM) was used for these analyses. 
4.4. Results  
4.4.1. Characterization of AAV5 Integration 
AAV5 integration was assessed by a combination of histological and molecular 
techniques. Brain sections from animals injected stereotaxically with either the control 
(rAAV5-GFAP-hIGF-1; Figure 4-1A) or the IGF-1 (rAAV5-GFAP-control; Figure 4-
1B) construct were visualized by fluorescent microscopy for the mCherry reporter. The 
mCherry reporter gene was located downstream of the constitutively expressed 
cytomegalovirus (CMV) promoter (see Figure 4-1), hence mCherry expression was 
widely distributed in neuronal and non-neuronal cells of the cortex (Figure 4-2Ai) and 
striatum (Figure 4-2Aii). mCherry expression was also localized to GFAP-
immunolabeled cells (Figure 4-2B), indicating that the viral construct was internalized to 
astrocytes. To assess whether the AAV5-GFAP-hIGF-1 construct was functional, 
sections from AAV5 injected animals were processed for hIGF-1 
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immunohistochemistry. No hIGF-1 positive cells were seen in animals injected with 
rAAV5-GFAP-control (Figure 4-2Ci), while hIGF-1 label (green; Figure 4-2Cii) was co-
localized to mCherry positive cells (red) in the rAAV5-GFAP-hIGF-1 treatment. Many 
of these double-labeled cells were located around blood vessels. 
Expression of hIGF-1 was further confirmed by qRT-PCR in whole brain 
homogenates and astrocyte homogenates. Astrocytes were collected by GLAST-positive 
selection by magnetic beads, using our previous procedures that results in a virtually 
pure astrocyte population (Chisholm et al. 2015). As expected, hIGF-1 was undetectable 
by qRT-PCR in whole hemisphere homogenates (Figure 4-2Di) and astrocytes 
homogenates (Figure 4-2Dii) from either the ischemic or non-ischemic hemisphere of 
animals injected with rAAV5-GFAP-control. In contrast, hIGF-1 was highly expressed 
in whole brain and astrocyte homogenates of the ischemic hemisphere of animals that 
were injected with AAV-GFAP-hIGF-1, with virtually no hIGF-1 gene expression in the 
non-ischemic hemisphere. There was no difference in the amount of rat IGF-1 
expression in tissue lysates and astrocytes regardless of hemisphere or treatment (Figure 
4-2Diii and 4-2Div). qRT-PCR of astrocyte homogenates used in these analyses show 
strong expression of GFAP, and virtually undetectable levels of PECAM (endothelial 







Figure 4-2: Integration of the AAV5 in the brain. 
AAV5 uptake into cells was detected by the mCherry reporter. A) At the striatal (Ai) and 
cortical (Aii) injection sites, both glial and neuronal cells were labeled by the mCherry 
reporter. B) Immunohistochemical labeling of GFAP in green and AAV5 mCherry 
reporter in red. Arrows indicate cells that are double labeled for AAV5 mCherry reporter 
and the glia marker GFAP. C) Immunohistochemistry for hIGF1 in green and AAV5 
mCherry reporter in red. hIGF-1 positive cells were seen in animals injected with 
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AAV5-GFAP-hIGF-1 (Cii) but not the AAV5-GFAP-control injected animals (Ci). 
hIGF-1 positive cells were colocalized to mCherry-labeled cells and mainly seen around 
blood vessels. D) mRNA expression of human and rat IGF-1 in harvested astrocytes. 
mRNA hIGF-1 expression was significantly only increased in the injected hemisphere 
site in whole brain (Di) and in harvested astrocytes (Dii). (N=5–8). No differences were 
seen in rat IGF-1 mRNA in whole brain lysates (N=4) (Diii) or astrocyte mRNA (N=6–
8) (Div). Magnetically harvested astrocytes produced a virtually pure population (E). 
(F(2, 18) = 7.132 P = 0.0052 Two-way ANOVA) (All graphs represent mean ± SEM). 
4.4.2. Post-Ischemic Survival 
Two doses of AAV5-GFAP-Control and AAV5-GFAP-hIGF-1 were injected 
into the striatum and cortex, a low dose of 2.5 × 1011 VP/mL and a high dose of 2.5 × 
1012 VP/mL. After 6–8 weeks post injection, all animals were subject to MCAo. In the 
high dose treatment, post-stroke mortality was higher in animals injected with the 
AAV5-GFAP-control as compared with AAV5-GFAP-hIGF-1 treated animals 
(p<0.0001; Figure 4-3A). High dose AAV5-GFAP-control animals did not survive more 
than 24 hours post-stroke, while high dose AAV5-GFAP-hIGF-1 treated animals 
survived 5 days, the predetermined termination point for this study. 
Animals that received the low dose AAV5 treatment did not show any 
differences in post-stroke mortality (Figure 4-3B; p = 0.8311). Both rAAV5-GFAP-
control and AAV5-GFAP-hIGF-1 groups survived until the predetermined termination 
point of the study at 5 days. Therefore, all subsequent studies were performed with the 




Figure 4-3: Post-ischemic survival 
  
Kaplan–Meier Survival Analysis for High Dose and Lose Dose. A) Animals who 
received the high dose AAV5-GFAP-hIGF-1 had significant survival post-stroke over 
120 hours (5 days) compared to high dose AAV5-GFAP-control (p<0.0001; n =7–10) B) 
Animals that received the lose dose AAV5-GFAP-hIGF-1 or AAV5-GFAP-control 
construct did not show differences in post-stroke survival over 120 hours (p=0.8311) 
(N= 4 – 5) 
4.4.3. Physiological measures affected by MCAo at the early acute period (2 days) 
post-stroke 
Physiological measures affected by MCAo at the early acute period (2 days) 
post-stroke 
Animals injected with AAV5-GFAP-control and rAAV5-GFAP-hIGF-1 were 
subject to ischemic stroke for 90 mins followed by reperfusion. Both groups experienced 
approximately 10% weight loss at 2 days post-stroke, which is commonly seen after 
stroke, however there was no difference in the extent of weight loss between the two 
groups (Figure 4-4A). Systolic blood pressure was also monitored pre- and post-stroke. 
Pre-stroke, AAV5-GFAP-control animals had a mean systolic blood pressure of 141.8 
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mmHg, and AAV5-GFAP-hIGF-1 animals averaged 133.9 mmHg. Post-stroke, the mean 
systolic blood pressure for AAV5-GFAP-control animals significantly decreased 24% to 
99.1 mmHg (p = 0.0098). The AAV-GFAP-hIGF-1 animals maintained a mean systolic 
blood pressure of 129.2 mmHg (Figure 4-4B). 
Infarct volume: Infarction was localized largely to the striatum, with smaller 
cortical infarcts. Infarct volume, assessed at 2 days post stroke, however, was similar 
between AAV5-GFAP-control and AAV5-GFAP-hIGF-1 groups (p = 0.3927; Figure 4-
4C). 
The neurological score, an indicator of motor disability, was significantly worse 
in AAV5-GFAP-control as compared to AAV5-GFAP-hIGF-1treated animals. Post-
stroke, AAV5-GFAP-control animals showed impaired mobility, righting reflex, 
grasping and pronounced circling behavior resulting in an average neurological score of 
3.86±0.89, which is typical of the post stroke disability observed in middle-aged female 
rats. 4. In contrast, AAV5-GFAP-hIGF-1 animals had significantly less impairment with 




Figure 4-4: Low dose post-ischemic outcomes 
A) No differences were seen between AAV5-GFAP-hIGF-1 and AAV5-GFAP-control 
treated animals in weight loss after stroke. (Unpaired t test; p=0.8675) B) AAV5-GFAP-
hIGF-1 treatment preserved systolic blood pressure. (F (1, 12) = 6.012, P = 0.0305; post 
hoc t-test for pre- and post-AAV5-GFAP-Control p = 0.0042). C) Neurological deficits 
were significantly decreased in the AAV5-GFAP-hIGF-1 animals as compared to the 
controls (unpaired t test; p = 0.0033). D) No differences found in infarct volumes 
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between groups (unpaired t test; p = 0.3927) (N= 7 – 8). All graphs represent mean ± 
SEM. 
 
4.4.4. Post-stroke sensory-motor behavioral outcomes 
To assess the effect of AAV5 treatment on sensory motor function post-stroke, 
the vibrissae evoked-forelimb placing task performance was assessed at 2 days (early 
acute phase) and 5 days (late acute phase) after MCAo. Consistent with other reports, 
sensory motor performance improved as animal progressed from the acute phase to the 
late phase. For the rAAV5-GFAP-control group, there was no response (NR) to either 
the same side or cross-midline test on the side contralateral to the ischemic side 
(contralesional) during the early acute phase (Figure 4-5Ai). In the AAV5-GFAP-hIGF-
1 group, during the early acute phase (2d post stroke), post-stroke performance was 
impaired compared to the pre-stroke performance, however animals in this group were 
still able to maintain about 45% of their pre-stroke responses to the vibrissae stimulation, 
unlike the AAV5-GFAP-Control group (F(3,24)=3.44; p=0.0359; Figure 4-5Ai). 
Similarly, on the ipsilesional side for the early acute phase, AAV5-GFAP-control 
had no responses to the same side test, while the AAV5-GFAP-hIGF-1 group maintained 
40% of their pre-stroke responses (F(3, 24) = 13.84; p<0.0001), although these were 
lower than the pre-stroke levels (F(1, 24) = 50.28; p<0.0001; Figure 4-5Aii). No loss of 
response was seen on the cross-midline task on the ipsilesional side. 
During the late acute phase (5 days post-stroke), improvement was noted in both 
groups, however performance in the AAV5-GFAP-control group was significantly 
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worse than pre-stroke levels (F(1, 14)=15.79; p = 0.0014). Specifically, AAV5-GFAP-
Control animals had lower responses on the same side (54%, p = 0.0294) and cross 
midline (42%, p = 0.0059) task on the paw contralateral to the infarct (Figure 4-5Bi). In 
contrast, performance of the AAV5-GFAP-hIGF-1 group was statistically no different 
from the pre-stroke performance (p = 0.9; Figure 4-5Bi and 4-5 Bii), indicating an 
improved rate of recovery. 
 
Figure 4-5: Vibrissae-Evoked Forelimb Placing Test 
Sensory motor performance was evaluated by vibrissae-evoked forelimb placing task at 
2 days (Ai and Aii) and 5 days (Bi and Bii) after stroke. Histogram depicts percent 
(+SEM) correct responses over 10 trials for tests of the contralesional (Ai and Bi) and 
ipsilesional (Aii and Bii) paw. NR: No Response; *: p<0.05), n= 7–8 for 2d post stroke, 




4.4.5. Blood brain barrier permeability 
Circulating levels of GFAP were analyzed as a surrogate measure of blood brain 
barrier permeability function (Marchi et al. 2004) from serum samples collected pre-
stroke, during the early acute and late acute phases of stroke. As shown in Figure 4-6A, 
GFAP was detected in all samples, however there was a main effect of stroke (pre and 
post-stroke) and treatment (AAV-GFAP-Control vs AAV-GFAP-IGF-1). GFAP levels 
were significantly elevated in both groups after stroke (F(1,27)= 7.32, p<0.05), and also 
significantly elevated by treatment (F(1,27)= 7.72, p<0.05) such that animals with AAV-
GFAP-hIGF-1 had significantly lower levels of GFAP. Planned comparisons showed 
that while the groups were no different at baseline, the AAV5-GFAP-hIGF-1 group had 
almost 50% lower levels of circulating GFAP as compared to the AAV5-GFAP-control 







Figure 4-6: Serum Analysis 
A) GFAP serum levels measured pre-stroke and at 2d and 5d post stroke in samples from 
AAV5-GFAP-control and AAV5-GFAP-hIGF-1 animals. a: main effect of AAV 
treatment; b: main effect of stroke, *: p>0.05; n=6–7. B) Cytokine levels of AAV5-
GFAP-control and AAV5-GFAP-hIGF-1 animals in serum samples taken pre-stroke and 
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2 days post stroke for G-CSF, IL-4, IL-12-p70, Eotaxin, and IL-5. (a: main effect of 
treatment; b: main effect of stroke) All graphs represent mean ± SEM. N = 6–7 in each 
group. 
 
4.4.6. Stroke-induced Inflammation 
 Serum Cytokines and Chemokines 
A panel of cytokines and chemokines were examined in serum at 2 days after 
MCAo for AAV5 treated animals. Almost all cytokines and chemokines were elevated 
after ischemia, while a subset were also affected by IGF-1 gene transfer. Compared to 
the rAAV5-control group (Figure 4-6B), the AAV5-GFAP-hIGF-1 groups showed 
elevated levels of G-CSF (main effect of treatment, p = 0.0048, and stroke, p = 0.0331), 
IL-4 (main effect of treatment, p = 0.0332, and stroke, p = 0.0005), IL-5 (main effect of 
treatment, p = 0.0216, and stroke, p = 0.0004), Eotaxin (main effect of treatment, p = 
0.0160, and stroke, p = 0.0011), and IL12-P70 (main effect of treatment, p = 0.0232, and 





Figure 4-7: Infiltrating regulatory T-cell Analysis 
A) Proportion of (CD45high) infiltrating immune cells detected in AAV5-GFAP-control 
and AAV5-GFAP-hIGF-1 treated animals (p = 0.4008). B) Proportion of CD4+ cells in 
AAV5-GFAP-control and AAV5-GFAP-hIGF-1 treated animals (p = 0. 0.3950). C) 
Proportion of infiltrating regulatory T-cells (CD45high, CD4/CD25/FoxP3) in AAV5-
GFAP-control and AAV5-GFAP-hIGF-1 treated animals (p = 0.0219). All graphs 




 Trafficking of peripheral immune cells 
Flow cytometry was used to determine whether AAV5-GFAP-hIGF-1 affected 
the cohort of immune cells trafficked to the ischemic hemisphere. Mononuclear cells 
were harvested from the brain 2 days post-stroke and sorted for cell markers for 
infiltrating cells. The proportion of infiltrating immune cells identified by high CD45 
expression was no different between the AAV5-GFAP-control and AAV5-GFAP-hIGF-
1 groups (p = 0.4008; Figure 4-7A). Similarly, there were no group differences between 
CD4 positive cells (p = 0.3950; Figure 4-7B), however the proportion of infiltrating 
regulatory T-cells, identified as CD45high/CD4/CD25/FoxP3 cells, was significantly 
elevated in the ischemic hemisphere of AAV5-GFAP-hIGF-1 treated animals as 
compared to AAV5-GFAP-control animals (p =0.0219; Figure 4-7C). 
In the case of infiltrating macrophages, identified by CD45high/CD11b/Iba1, 
there were no differences in the proportion of these invading cells in the AAV5-GFAP-
control and AAV5-GFAP-hIGF-1 groups (p = 0.2280; Figure 4-8A). However, 
infiltrating macrophages differed in the extent of M1 and M2 cohorts seen in each group. 
As shown in Fig 8B, the proportion of infiltrating macrophages labeled with 
CD68/CD86 (M1 phenotype) was decreased by 62% in AAV5-GFAP-IGF-1 treated 
animals as compared to AAV5-GFAP-control treated animals (p = 0.0485). In contrast, 
the proportion of infiltrating macrophages labeled with CD163/CD206 (M2 phenotype) 
was increased by 57% in AAV5-GFAP-hIGF-1 treated animals as compared to AAV5-




Figure 4-8: Infiltrating M1/M2 Macrophage Analysis 
A) Proportion of CD45high/CD11b/Iba1 stained cells (infiltrating macrophages) in 
AAV5-GFAP-control and AAV5-GFAP-hIGF-1 treated animals (p = 0.2280). B) 
Proportion of infiltrating M1 macrophages (CD45high/CD11b/Iba1/CD68/CD86 stained 
cells) in AAV5-GFAP-control and AAV5-GFAP-hIGF-1 treated animals (*: p = 0.0485) 
and infiltrating M2 macrophages (CD45high/CD11b/Iba1/CD163/CD206) (*: p = 
0.0248). All graphs represent mean ± SEM, n = 5–6 in each group. 
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4.4.7. Impact of rAAV5-GFAP-hIGF-1 in a permanent ischemia model 
In view of the perivascular location of rAAV-GFAP-hIGF-1 cells, we next 
determined whether replenishing astrocytic IGF-1 would be effective in a permanent 
ischemic model (i.e., no reperfusion). As shown in Figure 4-9, AAV5-GFAP-hIGF-1 
treatment had no effect on any of the measures tested. Similar to the transient MCAo, 
animals lost weight after stroke, and there were no group effects on weight loss (Figure 
4-9A). In case of the neurological score, AAV5-GFAP-control animals were 
significantly impaired after permanent MCAo (Figure 4-9B), averaging a score of 4 for 
both groups, similar to the deficiency seen in the transient MCAo for AAV5-GFAP-
control group (compare with Figure 4-4C). However, in the pMCAo condition, AAV5-
GFAP-hIGF-1 treatment had no effect on the neurological score (p = 0.9769). Infarct 
volume (Figure 4-9C; p = 0.7721) was also no different between the two groups, 
although mean infarct volume was much higher in this model than the transient ischemic 
model (Figure 4-4D). The vibrissae evoked forelimb placing task showed that both 
groups were severely impaired (Figure 4-4 Ei and Eii), and performance was not 
improved by AAV5-GFAP-hIGF-1. Overall, AAV5-GFAP-hIGF-1 had no protective 




Figure 4-9: Permanent MCAo Model 
A) Weight loss due to stroke in AAV5-GFAP-control and AAV5-GFAP-hIGF-1 treated 
animals. B) Neurological score assessed 2days after stroke in in AAV5-GFAP-control 
and AAV5-GFAP-hIGF-1 treated animals. C) Infarct volume measured 5d after stroke in 
AAV5-GFAP-control and AAV5-GFAP-hIGF-1 treated animals. Di and Dii) Sensory-
motor performance measured by vibrissae evoked forelimb placing task in AAV5-
GFAP-control and AAV5-GFAP-hIGF-1 treated animals. All graphs represent mean ± 




4.5. Discussion  
These data support the hypothesis that elevating IGF-1 expression in astrocytes 
significantly improves stroke outcomes after transient ischemia-reperfusion in middle-
aged female SD rats. AAV5 mediated-expression of hIGF-1 in astrocytes reduced 
stroke-induced motor impairment, improved sensory motor performance and preferential 
transmigration of immune cells associated with protective or anti-inflammatory actions. 
Additionally, systolic blood pressure was stable after transient MCAo in animals with 
replenished astrocyte IGF-1, while controls experienced a decrease in systolic blood 
pressure after stroke, which is associated with poorer clinical outcomes and increased 
mortality in stroke patients (Lin et al. 2015; Okin et al. 2015) especially in the acute 
period of stroke (Wohlfahrt et al. 2015). These novel findings are in accordance with a 
growing body of evidence that functional modifications of astrocytes yields major 
benefits for neurodegenerative diseases (Bajenaru et al. 2002; Furman et al. 2012; 
Furman et al. 2016). 
Age-regulated decreases in the functional capacity of astrocytes may increase the 
severity of neurological diseases. Aging astrocytes display decreased glucose uptake, 
GLUT1 expression, and glutathione (GSH) content (Souza et al. 2015), increased levels 
of intermediate glial fibrillary acidic protein and cytokine secretion (Capilla-Gonzalez et 
al. 2014; Salminen et al. 2011). Moreover, with age, astrocytes are less sensitive to the 
anti-inflammatory cytokine IL-10, which results in prolonged neuroinflammation due to 
persistent microglial activation (Norden et al. 2016). Our previous studies show that, 
compared to astrocytes from younger female rats, astrocytes from middle-aged females 
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have significantly reduced capacity for glutamate clearance, elevated expression of 
chemokines and increased ability to recruit PBMC in co-cultures (Lewis et al. 2012). 
More recent studies show that astrocytes from middle aged females have epigenetic 
modifications that cause transcriptional repression (Chisholm et al. 2015). This decline 
in astrocytic functional capacity coincides with an increase in infarct volumes and 
worsening post-stroke recovery in our model. Whether astrocyte dysfunction is the cause 
or the result of disease progression has yet to be elucidated. Nevertheless, astrocyte 
replacement by neural progenitor cells and glial-restricted precursors is reported to have 
some benefit in acute injury models such as spinal cord injury (Haas and Fischer 2013; 
van Gorp et al. 2013). 
Targeted modification of astrocyte proteins has been used in several neural injury 
models with success. In Huntington’s disease, AAV2/5 mediated restoration of Kir4.1, a 
rectifying potassium channel, in striatal astrocytes increased longevity and improved 
motor performance on the rotorad test, footprint analysis, and paw clasp test (Dvorzhak 
et al. 2016). In spinal cord injury, AAV8-mediated overexpression of Glutamate 
transporter 1, a protein found primarily in astrocytes, increased diaphragm dysfunction, 
affected breathing, and increased forelimb dysfunction six weeks after contusion (Li et 
al. 2014). In hippocampal ischemic injury, heat shock protein (Hsp)70 or superoxide 
dismutase (SOD) targeted for expression in astrocytes reduced cell death (Xu et al. 
2010) in vivo, while virally-mediated astrocyte specific expression of the excitatory 
amino acid transporter (EEAT2) decreased cell death in hippocampal cultures exposed to 
moderate oxygen glucose deprivation (OGD) (Weller et al. 2008). Interestingly, 
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enhanced expression of EEAT2 was only neuroprotective against moderate levels of 
OGD but not severe OGD (Weller et al. 2008). This was also seen in the present study 
where AAV5-mediated IGF-1 in astrocytes improved sensory motor function after 
stroke in transient MCA (Figure 4-5) but not permanent MCAo, which results in a much 
larger infarct volume (Figure 4-9) and is considered a more severe ischemic injury. In 
transient focal ischemia, suppression of CD38 in astrocytes reduced transfer of 
mitochondria, resulting in worse neurological outcomes. (Hayakawa, et. al., 2016). The 
unique finding of this study is that while non-cell specific viral-mediated transfer of 
IGF-1 either prior (Zhu et al. 2008) or after (Zhu et al. 2009) MCAo promotes 
neovascularization and neurogenesis, the present study is first demonstration that 
astrocyte targeted IGF-1 improves motor outcomes post-stroke. 
Surprisingly, while virally-mediated increase in astrocyte IGF-1 improved 
neurological scores and sensory motor performance and barrier function, it did not lead 
to reduction of infarct volume. While some studies have shown a significant correlation 
between increased infarct volume and worse neurological scores and motor impairment 
(Rogers et al. 1997), other studies showed no correlation between behavioral impairment 
and infarct volume (Wahl et al. 1992). Clinically, infarct volumes are not the strongest 
predictor of long-term prognosis unless combined with NIHSS scores (Baird et al. 
2001), as well as involvement of white matter tracts and cerebral blood supply (Heiss 
and Kidwell 2014). Furthermore, several other growth factors therapies also improve 
behavior independent of infarct volume. In SD rats, fibroblast growth factor treatment 
initiated 1 day after MCAo improved behavioral recovery but had no effect on infarct 
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volume (Kawamata et al. 1996). Similarly, rats infused with brain-derived neurotrophic 
factor after MCAo showed less functional deficit at 28 days after treatment than controls 
but lesion size measured by T2-MRI did not show differences at 7 and 28 days (Ramos-
Cejudo et al. 2015). Additionally, blocking ephrin-A5 signaling, an important pathway 
for axonal sprouting in premotor and prefrontal motor circuits, in reactive astrocytes 
after MCAo also improved motor function recovery without a significant change in 
infarct volume (Overman et al. 2012). 
The current studies also reveal a clear difference between the neuroprotective 
effects of intracerebroventricular (ICV) infusions of hIGF-1 versus AAV5-mediated 
astrocyte expression of hIGF-1. In middle-aged SD rats, intracerebroventricular (ICV) 
delivery of hIGF-1 after stroke significantly decreases infarct volume and reduces blood 
brain barrier permeability (Bake et al. 2014). Furthermore, ICV hIGF-1 treatment 
decreased trafficking of CD4+ cells and T regulatory cells into the ischemic hemisphere, 
consistent with the idea that IGF-1 reduces hyperpermeability at the blood brain barrier 
(Bake et al. 2016). In contrast, astrocyte-derived hIGF-1, did not improve infarct volume 
although barrier properties were improved as evidenced by serum GFAP levels. 
Furthermore, astrocyte hIGF-1 did not reduce overall immune trafficking into the 
ischemic hemisphere, but altered the cohort of immune subtypes. Thus, while there was 
no difference in the proportion of M1/M2 phenotype resident microglia, infiltrating 
regulatory T cells and infiltrating M2 macrophages were elevated, indicating that 
astrocyte-derived hIGF-1 altered immune cell transmigration to favor neuro-supportive 
and anti-inflammatory cells (Li et al. 2013; Liesz et al. 2015; Won et al. 2015). The 
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difference between the actions of ICV delivery of IGF-1 versus astrocyte mediated 
hIGF-1 could be due to differences in the amount of IGF-1 available via each method or 
due to the fact that virally-induced astrocyte hIGF-1 constitutes a ‘pretreatment’ while 
ICV-hIGF-1 is a post stroke treatment. Overall, our previous and current data support the 
hypothesis that the poorer stroke outcomes in older females is associated with age-
related decreases in this peptide hormone. 
Despite its central location, AAV5-mediated astrocyte hIGF-1 expression has 
striking effects on the peripheral physiological milieu, as seen by regulation of 
peripheral cytokines as well as maintenance of systolic blood pressure post-stoke. 
Astrocytic hIGF-1 elevated circulating levels of granulocyte colony-stimulating factor 
(GCSF), which is reported to be neuroprotective (Bath and Sprigg 2007; Fan et al. 2015; 
Shin and Cho 2016), as well as IL-4 and IL-5, which are associated with the Th2 
immune response and correlates with reduction in infarct volume (Luo et al. 2015). 
Peripheral inflammation in stroke patients, usually caused by infection, worsens stroke 
outcomes (Grau et al. 1999). LPS treatment after stroke, for example, increases 
macrophage infiltration and caused a prolonged impairment of hindlimb function 
(Langdon et al. 2010). Thus behavioral improvement seen in AAV-GFAP-hIGF-1 
infected animals may be mechanistically linked to a modification of the inflammatory 
environment. 
Astrocytes are the most abundant cell in the brain, outnumbering neurons by at 
least five to one (Cotrina and Nedergaard 2002; Sofroniew and Vinters 2010). Despite 
their abundance, stroke research has been mostly neurocentric, aimed towards 
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developing interventions focused on neuronal survival after ischemic injury (Barreto et 
al. 2011a; Lo et al. 2004), an approach that has not led to successful drug development 
(Barreto et al. 2011b). The recent trend towards targeting single genes in astrocyte shows 
promise as a therapy, although most studies have focused on young animal models. Our 
study is the first to show that correcting a growth factor deficiency in astrocytes in older 
animals can improve stroke outcomes. In conjunction with refinement of cell based 
stroke therapies, our data suggest that targeted elevation of IGF-1 in glial-restricted 
precursors may enhance stroke recovery in older or more susceptible patient populations. 
4.6. Main Points 
There are two major points of this study: 1) Ischemia-induced damage and 
disability is worse in middle-aged female rats than young female rats; and 2)Astrocyte-
specific gene transfer of IGF-1 improves the immunological response and motor sensory 
recovery after stroke in middle-aged females. 
4.7. References 
Abbott NJ, Ronnback L, Hansson E. Astrocyte-endothelial interactions at the blood-
brain barrier. Nat Rev Neurosci. 2006;7:41–53.  
 
Allaman I, Belanger M, Magistretti PJ. Astrocyte-neuron metabolic relationships: for 
better and for worse. Trends Neurosci. 2011;34:76–87.  
 
Ayadi AE, Zigmond MJ, Smith AD. IGF-1 protects dopamine neurons against oxidative 
stress: association with changes in phosphokinases. Exp Brain Res. 2016;234:1863–73.  
 143 
 
Badan I, Buchhold B, Hamm A, Gratz M, Walker LC, Platt D, Kessler C, Popa-Wagner 
A. Accelerated glial reactivity to stroke in aged rats correlates with reduced functional 
recovery. J Cereb Blood Flow Metab. 2003;23:845–54.  
 
Baird AE, Dambrosia J, Janket S, Eichbaum Q, Chaves C, Silver B, Barber PA, Parsons 
M, Darby D, Davis S, et al. A three-item scale for the early prediction of stroke 
recovery. Lancet. 2001;357:2095–9 
 
Bajenaru ML, Zhu Y, Hedrick NM, Donahoe J, Parada LF, Gutmann DH. Astrocyte-
specific inactivation of the neurofibromatosis 1 gene (NF1) is insufficient for 
astrocytoma formation. Mol Cell Biol. 2002;22:5100–13.  
 
Bake S, Okoreeh AK, Alaniz RC, Sohrabji F. Insulin-Like Growth Factor (IGF)-I 
Modulates Endothelial Blood-Brain Barrier Function in Ischemic Middle-Aged Female  
Rats. Endocrinology. 2016;157:61–9.  
 
Bake S, Selvamani A, Cherry J, Sohrabji F. Blood Brain Barrier and Neuroinflammation 
Are Critical Targets of IGF-1-Mediated Neuroprotection in Stroke for Middle-Aged 




Bano D, Young KW, Guerin CJ, Lefeuvre R, Rothwell NJ, Naldini L, Rizzuto R, 
Carafoli E, Nicotera P. Cleavage of the plasma membrane Na+/Ca2+ exchanger in 
excitotoxicity. Cell. 2005;120:275–85.  
 
Barreto G, White RE, Ouyang Y, Xu L, Giffard RG. Astrocytes: targets for 
neuroprotection in stroke. Cent Nerv Syst Agents Med Chem. 2011a;11:164–73.  
Barreto GE, Gonzalez J, Torres Y, Morales L. Astrocytic-neuronal crosstalk: 
implications for neuroprotection from brain injury. Neurosci Res. 2011b;71:107–13.  
 
Bath PM, Sprigg N. Colony stimulating factors (including erythropoietin, granulocyte 
colony stimulating factor and analogues) for stroke. Cochrane Database Syst Rev. 
2007:Cd005207. 
 
Bhat R, Crowe EP, Bitto A, Moh M, Katsetos CD, Garcia FU, Johnson FB, Trojanowski 
JQ, Sell C, Torres C. Astrocyte senescence as a component of Alzheimer’s disease. 
PLoS One. 2012;7:e45069. 
 





Buga AM, Sascau M, Pisoschi C, Herndon JG, Kessler C, Popa-Wagner A. The genomic 
response of the ipsilateral and contralateral cortex to stroke in aged rats. J Cell Mol Med. 
2008;12:2731–53. 
 
Capilla-Gonzalez V, Cebrian-Silla A, Guerrero-Cazares H, Garcia-Verdugo JM, 
Quinones-Hinojosa A. Age-related changes in astrocytic and ependymal cells of the 
subventricular zone. Glia. 2014;62:790–803.  
 
Cekanaviciute E, Buckwalter MS. Astrocytes: Integrative Regulators of 
Neuroinflammation in Stroke and Other Neurological Diseases. Neurotherapeutics. 
2016;13:685–701.  
 
Chisholm NC, Henderson ML, Selvamani A, Park MJ, Dindot S, Miranda RC, Sohrabji 
F. Histone methylation patterns in astrocytes are influenced by age following ischemia. 
Epigenetics. 2015;10:142–52.  
 
Chisholm NC, Sohrabji F. Astrocytic response to cerebral ischemia is influenced by sex 
differences and impaired by aging. Neurobiol Dis. 2016;85:245–53. 
 





Dienel GA, Hertz L. Astrocytic contributions to bioenergetics of cerebral ischemia. Glia. 
2005;50:362–88.  
 
Dvorzhak A, Vagner T, Kirmse K, Grantyn R. Functional Indicators of Glutamate 
Transport in Single Striatal Astrocytes and the Influence of Kir4.1 in Normal and 
Huntington Mice. J Neurosci. 2016;36:4959–75.  
 
Fan ZZ, Cai HB, Ge ZM, Wang LQ, Zhang XD, Li L, Zhai XB. The Efficacy and Safety 
of Granulocyte Colony-Stimulating Factor for Patients with Stroke. J Stroke 
Cerebrovasc Dis. 2015;24:1701–8.  
 
Furman JL, Sama DM, Gant JC, Beckett TL, Murphy MP, Bachstetter AD, Van Eldik 
LJ, Norris CM. Targeting astrocytes ameliorates neurologic changes in a mouse model 
of Alzheimer’s disease. J Neurosci. 2012;32:16129–40. 
 
Furman JL, Sompol P, Kraner SD, Pleiss MM, Putman EJ, Dunkerson J, Mohmmad 
Abdul H, Roberts KN, Scheff SW, Norris CM. Blockade of Astrocytic 
Calcineurin/NFAT Signaling Helps to Normalize Hippocampal Synaptic Function and 
Plasticity in a Rat Model of Traumatic Brain Injury. J Neurosci. 2016;36:1502–15. 
  
Grau AJ, Buggle F, Schnitzler P, Spiel M, Lichy C, Hacke W. Fever and infection early 
after ischemic stroke. J Neurol Sci. 1999;171:115–20.  
 147 
 
Haas C, Fischer I. Human astrocytes derived from glial restricted progenitors support 
regeneration of the injured spinal cord. J Neurotrauma. 2013;30:1035–52.  
 
Hayakawa K, Esposito E, Wang X, Terasaki Y, Liu Y, Xing C, Ji X, Lo EH. Transfer of 
mitochondria from astrocytes to neurons after stroke. Nature. 2016;535:551–5.  
 
Heiss WD, Kidwell CS. Imaging for prediction of functional outcome and assessment of 
recovery in ischemic stroke. Stroke. 2014;45:1195–201 
 
Jezierski MK, Sohrabji F. Neurotrophin expression in the reproductively senescent 
forebrain is refractory to estrogen stimulation. Neurobiol Aging. 2001;22:309–19.  
 
Karki P, Smith K, Johnson J, Jr, Lee E. Astrocyte-derived growth factors and estrogen 
neuroprotection: role of transforming growth factor-alpha in estrogen-induced 
upregulation of glutamate transporters in astrocytes. Mol Cell Endocrinol. 2014;389:58–
64.  
 
Kawamata T, Alexis NE, Dietrich WD, Finklestein SP. Intracisternal basic fibroblast 
growth factor (bFGF) enhances behavioral recovery following focal cerebral infarction 




Langdon KD, MacLellan CL, Corbett D. Prolonged, 24-h delayed peripheral 
inflammation increases short- and long-term functional impairment and 
histopathological damage after focal ischemia in the rat. Journal of Cerebral Blood Flow 
and Metabolism: Official Journal of the International Society of Cerebral Blood Flow 
and Metabolism. 2010;30:1450–1459.  
 
Latour A, Grintal B, Champeil-Potokar G, Hennebelle M, Lavialle M, Dutar P, Potier B, 
Billard JM, Vancassel S, Denis I. Omega-3 fatty acids deficiency aggravates 
glutamatergic synapse and astroglial aging in the rat hippocampal CA1. Aging Cell. 
2013;12:76–84.  
 
Lewis DK, Thomas KT, Selvamani A, Sohrabji F. Age-related severity of focal ischemia 
in female rats is associated with impaired astrocyte function. Neurobiol Aging. 
2012;33:1123, e1–16. 
 
Li K, Nicaise C, Sannie D, Hala TJ, Javed E, Parker JL, Putatunda R, Regan KA, Suain 
V, Brion JP, et al. Overexpression of the astrocyte glutamate transporter GLT1 
exacerbates phrenic motor neuron degeneration, diaphragm compromise, and forelimb 





Li P, Gan Y, Sun BL, Zhang F, Lu B, Gao Y, Liang W, Thomson AW, Chen J, Hu X. 
Adoptive regulatory T-cell therapy protects against cerebral ischemia. Ann Neurol. 
2013;74:458–71. 
 
Liesz A, Hu X, Kleinschnitz C, Offner H. Functional role of regulatory lymphocytes in 
stroke: facts and controversies. Stroke. 2015;46:1422–30. 
 
Lin MP, Ovbiagele B, Markovic D, Towfighi A. Systolic blood pressure and mortality 
after stroke: too low, no go? Stroke. 2015;46:1307–13.  
 
Lo EH, Broderick JP, Moskowitz MA. tPA and proteolysis in the neurovascular unit. 
Stroke. 2004;35:354–6.  
 
Lo EH, Dalkara T, Moskowitz MA. Mechanisms, challenges and opportunities in stroke. 
Nat Rev Neurosci. 2003;4:399–415. 
 
Luo Y, Zhou Y, Xiao W, Liang Z, Dai J, Weng X, Wu X. Interleukin-33 ameliorates 
ischemic brain injury in experimental stroke through promoting Th2 response and 
suppressing Th17 response. Brain Res. 2015;1597:86–94.  
 
Madathil SK, Carlson SW, Brelsfoard JM, Ye P, D’Ercole AJ, Saatman KE. Astrocyte-
Specific Overexpression of Insulin-Like Growth Factor-1 Protects Hippocampal 
 150 
 
Neurons and Reduces Behavioral Deficits following Traumatic Brain Injury in Mice. 
PLoS One. 2013;8:e67204. 
 
Manwani B, Liu F, Xu Y, Persky R, Li J, McCullough LD. Functional recovery in aging 
mice after experimental stroke. Brain Behav Immun. 2011;25:1689–700. 
  
Marchi N, Cavaglia M, Fazio V, Bhudia S, Hallene K, Janigro D. Peripheral markers of 
blood–brain barrier damage. Clinica Chimica Acta. 2004;342:1–12. 
  
Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, de Ferranti S, 
Després J-P, Fullerton HJ, Howard VJ, et al. Heart Disease and Stroke Statistics—2015 
Update. A Report From the American Heart Association. 2015;131:e29–e322.  
 
Norden DM, Trojanowski PJ, Walker FR, Godbout JP. Insensitivity of astrocytes to 
interleukin 10 signaling following peripheral immune challenge results in prolonged 
microglial activation in the aged brain. Neurobiol Aging. 2016;44:22–41.  
 
Okin PM, Kjeldsen SE, Devereux RB. Systolic Blood Pressure Control and Mortality 




Olsen ML, Sontheimer H. Functional implications for Kir4.1 channels in glial biology: 
from K(+) buffering to cell differentiation. Journal of Neurochemistry. 2008;107:589–
601. 
 
Overman JJ, Clarkson AN, Wanner IB, Overman WT, Eckstein I, Maguire JL, Dinov 
ID, Toga AW, Carmichael ST. A role for ephrin-A5 in axonal sprouting, recovery, and 
activity-dependent plasticity after stroke. Proc Natl Acad Sci U S A. 2012;109:E2230–9.  
 
Panickar KS, Norenberg MD. Astrocytes in cerebral ischemic injury: morphological and 
general considerations. Glia. 2005;50:287–98.  
 
Posada-Duque RA, Barreto GE, Cardona-Gomez GP. Protection after stroke: cellular 
effectors of neurovascular unit integrity. Front Cell Neurosci. 2014;8:231. 
 
Ramos-Cejudo J, Gutiérrez-Fernández M, Otero-Ortega L, Rodríguez-Frutos B, Fuentes 
B, Vallejo-Cremades MT, Hernanz TN, Cerdán S, Díez-Tejedor E. Brain-Derived 
Neurotrophic Factor Administration Mediated Oligodendrocyte Differentiation and 
Myelin Formation in Subcortical Ischemic Stroke. Stroke. 2015;46:221–228. 
 
Ridet JL, Malhotra SK, Privat A, Gage FH. Reactive astrocytes: cellular and molecular 




Rogers DC, Campbell CA, Stretton JL, Mackay KB. Correlation Between Motor 
Impairment and Infarct Volume After Permanent and Transient Middle Cerebral Artery 
Occlusion in the Rat. Stroke. 1997;28:2060–2066.  
 
Rossi DJ, Brady JD, Mohr C. Astrocyte metabolism and signaling during brain ischemia. 
Nat Neurosci. 2007;10:1377–1386.  
 
Salminen A, Ojala J, Kaarniranta K, Haapasalo A, Hiltunen M, Soininen H. Astrocytes 
in the aging brain express characteristics of senescence-associated secretory phenotype. 
Eur J Neurosci. 2011;34:3–11. 
 
Selvamani A, Sohrabji F. The neurotoxic effects of estrogen on ischemic stroke in older 
female rats is associated with age-dependent loss of IGF-1. The Journal of 
Neuroscience: the official journal of the Society for Neuroscience. 2010;30:6852–6861. 
 
Shin YK, Cho SR. Exploring Erythropoietin and G-CSF Combination Therapy in 
Chronic Stroke Patients. Int J Mol Sci. 2016;17:463. 
 





Souza DG, Bellaver B, Raupp GS, Souza DO, Quincozes-Santos A. Astrocytes from 
adult Wistar rats aged in vitro show changes in glial functions. Neurochem Int. 
2015;90:93–7.  
 
Topp KS, Faddis BT, Vijayan VK. Trauma-induced proliferation of astrocytes in the 
brains of young and aged rats. Glia. 1989;2:201–11. 
 
Utada K, Ishida K, Tohyama S, Urushima Y, Mizukami Y, Yamashita A, Uchida M, 
Matsumoto M. The combination of insulin-like growth factor 1 and erythropoietin 
protects against ischemic spinal cord injury in rabbits. J Anesth. 2015;29:741–8.  
 
van Gorp S, Leerink M, Kakinohana O, Platoshyn O, Santucci C, Galik J, Joosten EA, 
Hruska-Plochan M, Goldberg D, Marsala S, et al. Amelioration of motor/sensory 
dysfunction and spasticity in a rat model of acute lumbar spinal cord injury by human 
neural stem cell transplantation. Stem Cell Res Ther. 2013;4:57.  
 
Wahl F, Allix M, Plotkine M, Boulu RG. Neurological and behavioral outcomes of focal 
cerebral ischemia in rats. Stroke. 1992;23:267–72.  
 
Weller ML, Stone IM, Goss A, Rau T, Rova C, Poulsen DJ. Selective Over Expression 
Of EAAT2 In Astrocytes Enhances Neuroprotection From Moderate But Not Severe 
Hypoxia-Ischemia. Neuroscience. 2008;155:1204–1211.  
 154 
 
Wohlfahrt P, Krajcoviechova A, Jozifova M, Mayer O, Vanek J, Filipovsky J, Cifkova 
R. Low blood pressure during the acute period of ischemic stroke is associated with 
decreased survival. J Hypertens. 2015;33:339–45.  
 
Won S, Lee JK, Stein DG. Recombinant tissue plasminogen activator promotes, and 
progesterone attenuates, microglia/macrophage M1 polarization and recruitment of 
microglia after MCAO stroke in rats. Brain Behav Immun. 2015;49:267–79.  
 
Woodlee MT, Asseo-Garcia AM, Zhao X, Liu SJ, Jones TA, Schallert T. Testing 
forelimb placing “across the midline” reveals distinct, lesion-dependent patterns of 
recovery in rats. Exp Neurol. 2005;191:310–7. 
 
Xie L, Yang SH. Interaction of astrocytes and T cells in physiological and pathological 
conditions. Brain Res. 2015;1623:63–73.  
 
Xu L, Emery JF, Ouyang YB, Voloboueva LA, Giffard RG. Astrocyte targeted 
overexpression of Hsp72 or SOD2 reduces neuronal vulnerability to forebrain ischemia. 
Glia. 2010;58:1042–9. 
 
Zhu W, Fan Y, Frenzel T, Gasmi M, Bartus RT, Young WL, Yang GY, Chen Y. Insulin 
growth factor-1 gene transfer enhances neurovascular remodeling and improves long-
term stroke outcome in mice. Stroke. 2008;39:1254–61. 
 155 
 
Zhu W, Fan Y, Hao Q, Shen F, Hashimoto T, Yang G-Y, Gasmi M, Bartus RT, Young 
WL, Chen Y. Postischemic IGF-1 gene transfer promotes neurovascular regeneration 
after experimental stroke. Journal of cerebral blood flow and metabolism: official 




5.1. Insulin-like Growth Factor-1 Protects the Blood Brain Barrier  
Insulin-like growth factor-1, a neuroprotective peptide hormone for our aging 
female model (Bake, Selvamani, Cherry, & Sohrabji, 2014), is secreted each cell of the 
neurovascular unit: astrocytes, endothelial cells, neurons, microglial cells, and pericytes 
(Fernandez & Torres-Aleman, 2012; Nishijima et al., 2010; Sohrabji, Bake, & Lewis, 
2013; Zhu et al., 2008). Previous studies have shown that IGF-1 decreases post-stroke 
inflammation and infarct volumes (Bake et al., 2014). This research approaches the 
benefits and mechanisms of IGF-1 post-stoke neuroprotection in our aging female model 
by focusing on non-neuronal cell types and endothelial cells with the hope of 
implementing IGF-1 as a possible post-stroke treatment, particularly in females.  
The research within this dissertation tests the hypothesis that insulin-like growth factor-1 
reduces brain infarction acts by preserving the integrity of the blood brain barrier after 
ischemia in females. 
The research presented within this dissertation repeatedly provides evidence 
supporting this hypothesis by using both in vivo and in vitro methodology. In the first 
study, post-stroke IGF-1 treatment, in vivo, decreases two surrogate markers of blood 
brain barrier permeability, both CD4+ and Treg cells that are harvested from ischemic 
middle-aged female rat brain. The study goes further to understand the molecular details 
by harvesting brain microvascular endothelial cells (BMEC)s from middle-aged female 
rats and subjecting them to stroke-like conditions (OGD), in vitro. IGF-I treatment to 
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these BMECs significantly reduces the transfer of fluorescently labeled BSA across a 
BMEC monolayer and reduces ischemia-induced morphological changes in BMECs. 
These data suggest that, in our female aging model, IGF-1 supports blood brain barrier 
function and integrity after ischemia, specifically, by acting on brain microvascular 
endothelial cells.  
Building on the results from the first study, the second study also applies in vivo 
and in vitro methodologies to further investigate the neuroprotective effects of IGF-1 on 
the female BBB during ischemia, honing in on brain microvascular endothelial cells. 
The architecture of post-stroke microvascular in our aging model was analyzed to 
determine if the BMEC morphology changes seen in vitro in the first study translated in 
vivo. Post-stroke IGF-1 treatment prevented microvascular collapse. In addition, Post-
stroke IGF-1 preserved vinculin, an important protein which anchors vessels to the 
basement membrane. Both findings suggests that post-stroke IGF-1 preserves BBB 
integrity. In vitro, IGF-1 reduced ischemic-induced stress fiber formation in female 
BMECs, correlating F-actin formation to the morphological changes seen in BMEC 
from the first study. All together these data strongly suggests that BMECs are a major 
target of post-stroke IGF-1 neuroprotection in our aging female model and that IGF-1 
mitigates the ischemia-induced morphological and molecular responses of BMECs 
which results in increased BBB permeability and neurotoxic inflammation.  
The third study approaches the dissertation overall hypothesis by targeting a cell 
that is intimately associated with BBB, the astrocyte, a cell of neurovascular unit 
(Abbott, 2002; Abbott & Friedman, 2012; Abbott, Ronnback, & Hansson, 2006). Gene 
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transfer of IGF-1 specifically in astrocytes prior to ischemic improves post-stroke 
outcomes and decreased BBB permeability, as assessed by serum GFAP, a surrogate 
marker (Marchi et al., 2003; Park & Sohrabji, 2016). This study, unlike when IGF-1 is 
provided ICV, demonstrates that targeted treatment to the microvasculature post-stroke 
is enough to improve recovery, further suggesting IGF-1 act at the level of the BBB to 
improve post-stroke outcomes.  
Taken together, this data implies that insulin-like growth factor-1 acts by 
preserving the integrity of the blood brain barrier after ischemia in females and is a 
likely candidate for the stroke therapy in women. Though these studies in this 
dissertation are limited to the acute phase of stroke recovery, in other studies, our 
laboratory has shown that early post-stroke IGF-1 treatment improves outcomes several 
months after injury.   
As previously mentioned, stroke is an extremely deadly, debilitating disease, 
particularly for women, with very few interventions. The work presented here further 
suggests that IGF-1 is poised to address the dire need for neurovascular treatments. IGF-
1 has great promise in providing an improved treatment option for older women. 
Compared to tPA, IGF-1 is likely to have a wider therapeutic window than 4.5 hour after 
onset (Davis & Donnan, 2009), allowing IGF-1 to serve a wider proportion of stroke 
patients, and IGF-1 is likely not to have the acute life-threatening risk associated with 




5.2. Further Work and Challenges 
To translate IGF-1 from benchtop to bedside, more research on its 
neuroprotective effects is needed. Though the work presented here furthers our 
understanding of the effects of IGF-1 on the ischemic brain, the precise mechanisms and 
parameters of IGF-1 are poorly understood. Critical research issues follow. 
5.2.1. The Therapeutic Window of IGF-1 
A major result from the second study was that IGF-1 treatment after stroke 
resulted in significant biological changes in the early stages of stroke recovery, however 
these effects waned over time. But despite the lack of biological differences between 
vehicle and IGF-1 treatment at the later time points, IGF-1 improved long-term 
assessments of sensory motor function in the middle-aged female animal model. 
However, it is unknown how long after a stroke IGF-1 can be provided with a significant 
benefit in the middle-aged female model.  
Stroke patients are not always able to come to a medical facility rapidly after the 
onset of stroke (Fields & Levine, 2005). This often means that they are not eligible for 
tPA treatment, which can only be administered 3-4.5 h after stroke. It would be 
important to determine if IGF-1 treatment is neuroprotective if given at progressively 
longer times after stroke. This would include hours to days after the onset of stroke. As 
these studies show, both morphological, biochemical and behavioral assessments should 
be used. If IGF-1 is still beneficial 24 hours after stroke, it will be a significant 
advancement over other current therapies including tPA. Though the effect may not be 
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as dramatic as early treatment, any improvement seen at the later treatment-onset time 
point would have a significant clinical impact.  
5.2.2. The Long Term Effects & Toxicity of IGF-1 
All the studies in this thesis have focused on recovery in the acute phase of 
stroke, such as neurological score and sensory motor deficits. However, stroke also 
results in long term disability, and other psychiatric conditions such as post-stroke 
depression (Thomas et al., 2016), post-stroke epilepsy (Kim, Park, Choi, & Lee, 2016), 
and changes in addictive behaviors (Abdolahi et al., 2015a, 2015b; Brust & Richter, 
1976). Future studies need to focus on the effect of long term recovery, using a variety 
of outcome measures. 
An important issue that also needs to be addressed in preclinical studies is the 
toxicity of the IGF-1. As a growth hormone, there is some concern that the systemic 
injections of IGF-1 would lead to an increased risk of cancer. Long term studies 
therefore need to also include full body histopathology to exclude the possibility of 
tumor development. Due the short time period of IGF-1 treatment post-stroke, we 
believe it is unlikely that IGF-1 will be a reliable cause of cancer.  
Another concern in the clinical application of IGF-1 is hypoglycemia. As an 
anabolic agent, IGF-1 can decrease glucose level when provided intravenously (Di Cola, 
Cool, & Accili, 1997; Kovacs et al., 1999). In rats, this effect has rapid-onset and is 
dose-dependent. Again, it is unlikely to occur at the low doses needed for 
neuroprotection, but such effects would have to be tested in the aged female model 
before human testing. Also, in the presence of others metabolic disorders, such diabetes 
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which is a risk factor for stroke, the detrimental metabolic effects of IGF-1 may be 
amplified. 
5.2.3. Molecular Pathways of IGF-1 
To translate IGF-1 to the clinic, we need a more thorough understanding of IGF-
1’s neuroprotective mechanism of action, to better predict drug interactions. In this 
context in vitro studies would be most effective in understanding signaling pathways, 
using a combination of gene silencing techniques or pharmacological tools. As the 
second study shows, the effect of IGF-1 in vitro can mirror events that occurred in vivo, 
suggesting in vitro modeling is a useful tool to assess the mechanism of IGF-1. The in 
vitro model would also be useful in investigating    the delayed effects of IGF-1.  
In the brain, all cells of the neurovascular unit secrete IGF-1 and provides both autocrine 
and paracrine input (Bassil, Fernagut, Bezard, & Meissner, 2014). Once released IGF-1 
binds to IGF-1R, this binding activates the tyrosine kinase domains on the β subunits of 
IGF-1R (the major target of JB-1, our IGF-1 antagonist), leading to the activation of the 
canonical PI3K/mTOR/AKT and MAPK/ERK pathways, two important signaling 
cascades proliferation, cell cycle, and survival within the brain (Alonso & Gonzalez, 
2012). Our laboratory has shown that post-stroke IGF-1 treatment does increase 
expression of phosphorylated of AKT and ERK expression (Bake et al., 2014). In 
addition, other researchers have connected to the endothelial stress response to IGF-1 
signaling (Panganiban & Day, 2013; Yentrapalli et al., 2013).   
Since it known which pathways is most consequence for IGF-1 neuroprotection, 
the next step could be to knock down loci on the PI3K/mTOR/AKT and MAPK/ERK 
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pathways in separate experiments with OGD. The PI3K/mTOR/AKT pathway can be 
targeted using Wortmannin which targets PI3K (Wang et al., 2016), rapamycin which 
targets mTOR (C. Y. Li et al., 2015), or MK-2206 2HCl which targets (L. Zhang et al., 
2015). The MAPK/ERK pathway can be targeted using SB203580 which targets MAPK 
(Dong et al., 2014) and SCH772984 which targets ERK (Abravanel et al., 2015). After 
knocking down, to further confirm the role each of these loci, the members of the 
pathway can be upregulated by gene transfer in presence of JB-1 plus IGF-1 to 
determine if the stress responses to OGD are reduced. Rho GTPases inhibitors can also 
be used to investigate stress fiber formation. Using these pharmacological agents, a 
stronger understanding of the neurological protective pathway of IGF-1 can be achieved. 
5.2.4. Interaction of Endothelial Cells and Astrocytes 
Thorough the three studies in the dissertation, endothelial cells and astrocytes, 
two important of glial cells of NVU, were shown to be affected by our treatments. In 
vivo, our data suggest that astrocyte derived IGF-1 affects the blood brain barrier 
presumably by acting on endothelial cells. However, this interaction between glia and 
endothelial cells was not directly tested. To more accurately replicated BBB in vitro, 
IGF-1’s effects should be examined in co-culture of astrocytes and endothelial cells. 
Studies in this dissertation show that the early morphological BMEC changes are 
receptor mediated, which is not surprising. However, more mechanistic details are 
needed to better understand the post stroke vascular collapse seen in vivo.  One approach 
to investigate this would be to systemically knock down loci in the canonical 
PI3K/mTOR/AKT and MAPK/ERK pathways cascade specifically and conditionally in 
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endothelial cells. This can be done in vivo using knockout mice or CRISPR/Cas9 
technology and in vitro using siRNA.  
5.2.5. Stem Cell Therapy  
The most exciting result of this research was showcasing that restoring the 
secretion of one peptide hormone (IGF-1)  by a single CNS cell type (astrocyte) can 
have significant consequences for stroke recovery in an aged female model. This result 
invites the question: Will introducing cells with increased IGF-1 secretion post-stroke 
improve outcomes and recovery?    
Steps towards approaching this question having already in progress. Bone 
marrow-derived mesenchymal stem cells (BMDSC) are being used in stroke with 
moderate success (Steinberg et al., 2016). There is a phase 1/2a trial with eighteen 
patients that were provided post-stroke BMDSCs treatment for chronic stroke. After 12 
month after treatment, these patients showed improvement in European Stroke Scale, 
National Institutes of Health Stroke Scale, and Fugl-Meyer total score (Steinberg et al., 
2016). However, the BMDSC did not show any improvement in the modified Rankin 
Scale, the most widely used clinical measure of global neurological function and 
behavior after stroke during any time points after treatment (Harrison, McArthur, & 
Quinn, 2013). We have showed IGF-1 improves behavior well after post-stroke 
treatment, implying that IGF-1 would be a suitable supplement to this stem cell 
treatment. This implies the current  BMDSC have also shown great promise in the other 
acute CNS injury models, such as spinal cord injury (Yousefifard et al., 2016) and 
traumatic brain injury (Jiang, Bu, Liu, & Cheng, 2012). The research presented here 
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suggests that priming BMDSC with increased IGF-1 secretion using gene transfer before 
post-stroke injection would be more efficacious than the currently unmodified BMDSC, 
increasing patient recovery and behavioral health. This type of strategy is already being 
explored in other research areas (M. Li et al., 2010; Tao et al., 2016).  
There are potential pitfalls to address. Introducing a cell into the CNS that 
continuously produces IGF-1 would likely increase the opportunity for unwanted cell 
growth. AAV5 typically does not integrate into the host genome, thus gene transfer is 
loss after replication. This may cause some moderate issues in cell culture, however it 
may be advantageous once the stem cells are activated in the brain. As these cells divide 
and differentiate in the brain, the level of IGF-1 overexpression should decrease 
exponentially over time. This would be advantageous since long term IGF-1 
replenishment poses a risk for cancer and there is building evidence that suggests IGF-1 
treatment would be most beneficial in the early phases of stroke recovery. 
5.3. Final Words 
Stroke is a markedly expensive U.S. health concern that does not have a clear 
sign of waning as life spans expands, as food deserts swell thorough the heartland and 
the wealth inequality continues to stifle the majority of Americans from making 
responsible food choices and health decisions. Stroke particularly affects the lives of 
women, both in terms of mortality and increased disability. The studies in this thesis 
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